


PATENT COOPERATION TREATY

PCT



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| | | |
|---|---|---|
| Applicant's or agent's file reference HMR99L037PCT | FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) | |
| International application No. PCT/EP00/05921 | International filing date (day/month/year) 26/06/2000 | Priority date (day/month/year) 02/07/1999 |
| International Patent Classification (IPC) or national classification and IPC C07D473/34 | | |
| Applicant AVENTIS PHARMA DEUTSCHLAND GMBH et al. | | |

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 6 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☒ Certain documents cited
- VII ☒ Certain defects in the international application
- VIII ☒ Certain observations on the international application

| | |
|---|--|
| Date of submission of the demand 20/01/2001 | Date of completion of this report 31.08.2001 |
| Name and mailing address of the international preliminary examining authority: <div style="display: flex; align-items: center;"> <div> European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 </div> </div> | Authorized officer Stroeter, T Telephone No. +49 89 2399 8088 |



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP00/05921

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-60 as originally filed

Claims, No.:

1-10 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/EP00/05921

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

| | | |
|-------------------------------|-------------|------|
| Novelty (N) | Yes: Claims | |
| | No: Claims | 1-10 |
| Inventive step (IS) | Yes: Claims | |
| | No: Claims | 1-10 |
| Industrial applicability (IA) | Yes: Claims | 1-10 |
| | No: Claims | |

**2. Citations and explanations
see separate sheet**

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VII. Certain defects in the international application

The following defects in the form or contents of the international application have been noted:
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/05921

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1 Prior art documents

Reference is made to the following documents. The given numbering will be adhered to in the rest of the procedure:

- D1: EP-A-0 853 084 (HOECHST AG ;GENENTECH INC (US))
- D2: WO 98 31359 A (DUGGAN MARK E ;MERCK & CO INC (US))
- D3: WO 98 18461 A (HOFFMAN WILLIAM F ;DUGGAN MARK E (US); IHLE NATHAN C (US); MERCK &)
- D4: WO 95 32710 A (MERCK & CO INC ;HARTMAN GEORGE D (US); DUGGAN MARK E (US); IHLE NA)
- D5: WO 98 08840 A (HOFFMAN WILLIAM F ;HUTCHINSON JOHN H (US); MEISSNER ROBERT S (US);)
- D6: please see section VI.

D1 to D6 reveal compounds which are active as vitronectin receptor antagonists.

2 Novelty (Article 33(2) PCT) and Inventive step (Article 33(3) PCT)

D2 to D6 do only contain compounds which do not contain a 6-cyclohexyl (or 6-piperidin-1-yl or 6-piperazin-1-yl, respectively) substituted purine moiety as the presently claimed compounds and thus are not structurally closely related. These documents are therefore not further considered.

Article 33(2) PCT: D1, however, is novelty-destroying for the present claims: The subject-matter of present claims 1-5 overlaps with the subject-matter of claims 1-5 of D1. Claim 6 of D1 contains thus even more relevant novelty-destroying subject-matter since this claim contains certain compounds differing only in R³ and wherein the group R⁶SO₂N(R⁵)R⁷ is specifically mentioned in the list of possible moieties for R³.

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/05921

Therefore said present claims 1-5 (and their related claims 6-10) are not novel.

Article 33(3) PCT: Although no specific examples having a sulfonamide moiety were disclosed in D1, the restricted scope of claim 6 of D1 makes clear to the skilled man that the oxycarbonylamino groups present in the example compounds of D1 can be replaced by a sulfonamide moiety while retaining the vitronectin receptor antagonistic activity when also considering the content of either D2, D3 or D4. These documents show many vitronectin receptor antagonists having a sulfonamide moiety.

Thus, on condition that the Applicant is able to provide a set of novel claims, it is furthermore necessary to file comparative data showing an advantageous effect, i.e. a stronger vitronectin receptor antagonistic activity compared to the example compounds of D1 in order to render such claims inventive.

The claims 1-10 are at present neither novel nor inventive and as such do not fulfil the requirements of Articles 33(2) and (3) PCT.

3 Industrial applicability (Article 33(4) PCT)

The subject-matter of the present set of claims 1 to 10 is in accordance with the requirements of Article 33(4) PCT.

Re Item VI

Certain documents cited

The International Search Report mentions one P-document D6, which does not form part of the state of the art according to Rule 64.1(b) PCT:

D6: WO 99 37621 A (CUTHBERTSON ROBERT ANDREW ;SCHEUNEMANN
KARLHEINZ (DE); KNOLLE JOCH)

The Applicant is informed, that D6 does not contain novelty destroying subject matter

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/EP00/05921

Re Item VII

Certain defects in the international application

On page 4, paragraph 2 of the description some application numbers of certain PCT documents are cited. Their publication numbers should be mentioned instead.

Re Item VIII

Certain observations on the international application

The vague term "prodrug" in claims 1-10 causes lack of clarity (Article 6 PCT) because the scope of said claims is thus not exactly defined and therefore said term has to be excelled from the present set of claims.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| | | | |
|--|---|--|--|
| Applicant's or agent's file reference HMR99L037PCT | FOR FURTHER ACTION | | see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below. |
| International application No. PCT/EP 00/ 05921 | International filing date (day/month/year) 26/06/2000 | (Earliest) Priority Date (day/month/year) 02/07/1999 | |
| Applicant AVENTIS PHARMA DEUTSCHLAND GMBH et al. | | | |

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.



It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.



the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :



contained in the international application in written form.



filed together with the international application in computer readable form.



furnished subsequently to this Authority in written form.



furnished subsequently to this Authority in computer readable form.



the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.



the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2.



Certain claims were found unsearchable (See Box I).

3.



Unity of Invention is lacking (see Box II).

4. With regard to the **title**,



the text is approved as submitted by the applicant.



the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,



the text is approved as submitted by the applicant.



the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.



as suggested by the applicant.



because the applicant failed to suggest a figure.



because this figure better characterizes the invention.



None of the figures.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

VIEILLEFOSSE, Jean-Claude
Aventis Pharma S.A.
102, route de Noisy
F-93235 Romainville Cedex
FRANCEDate of mailing (day/month/year)
13 March 2001 (13.03.01)Applicant's or agent's file reference
HMR99L037PCT

IMPORTANT NOTIFICATION

International application No.
PCT/EP00/05921International filing date (day/month/year)
26 June 2000 (26.06.00)

1. The following indications appeared on record concerning:

☐ the applicant ☐ the inventor ☒ the agent ☐ the common representative

Name and Address

VIEILLEFOSSE, Jean-Claude
Hoechst Marion Roussel
102, route de Noisy
F-93235 Romainville Cedex
France

State of Nationality

State of Residence

Telephone No.

0149 91 57 27

Facsimile No.

0149 91 46 10

Teleprinter No.

2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person ☒ the name ☐ the address ☐ the nationality ☐ the residence

Name and Address

VIEILLEFOSSE, Jean-Claude
Aventis Pharma S.A.
102, route de Noisy
F-93235 Romainville Cedex
France

State of Nationality

State of Residence

Telephone No.

0149 91 57 27

Facsimile No.

0149 91 46 10

Teleprinter No.

3. Further observations, if necessary:

The indication of a new company's name of the agent on the Demand (Form PCT/IPEA/401) has been considered a request for recording a change under Rule 92bis. In case of disagreement, the International Bureau should be notified immediately.

4. A copy of this notification has been sent to:

☒ the receiving Office ☐ the designated Offices concerned
☐ the International Searching Authority ☒ the elected Offices concerned
☒ the International Preliminary Examining Authority ☐ other:The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Authorized officer

Claudio Borton

Facsimile No.: (41-22) 740.14.35

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner
 US Department of Commerce
 United States Patent and Trademark
 Office, PCT
 2011 South Clark Place Room
 CP2/5C24
 Arlington, VA 22202
 ETATS-UNIS D'AMERIQUE
 in its capacity as elected Office

| | |
|---|---|
| Date of mailing (day/month/year) 13 March 2001 (13.03.01) | |
| International application No. PCT/EP00/05921 | Applicant's or agent's file reference HMR99L037PCT |
| International filing date (day/month/year) 26 June 2000 (26.06.00) | Priority date (day/month/year) 02 July 1999 (02.07.99) |
| Applicant PEYMAN, Anuschirwan et al | |

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:
 20 January 2001 (20.01.01)

☐ in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

| | |
|---|--|
| The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35 | Authorized officer Claudio Borton Telephone No.: (41-22) 338.83.38 |
|---|--|

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02399 A1

(51) International Patent Classification⁷: C07D 473/34,
A61K 31/52

rue de la Biberonne, F-77410 Claye Souilly (FR). RUXER,
Jean-Marie [FR/FR]; 12, Esplanade de la Manufacture,
F-92130 Issy les Moulineaux (FR).

(21) International Application Number: PCT/EP00/05921

(22) International Filing Date: 26 June 2000 (26.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
99112637.6 2 July 1999 (02.07.1999) EP

(74) Agent: VIEILLEFOSSE, Jean-Claude; Hoechst Marion
Roussel, 102, route de Noisy, F-93235 Romainville Cedex
(FR).

(71) Applicants (for all designated States except US): AVEN-
TIS PHARMA DEUTSCHLAND GMBH [DE/DE];
Brüningsstrasse 50, D-65929 Frankfurt am Main (DE).
GENENTECH INC. [US/US]; 1 DNA Way, South San
Francisco, CA 94080-4990 (US).

(81) Designated States (national): AE, AG, AL, AU, BA, BB,
BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE,
HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV,
MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK,
TR, TT, UA, US, UZ, VN, YU, ZA.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): PEYMAN,
Anuschirwan [DE/DE]; Zeilsheimer Strasse 46, D-65779
Kelkheim (DE). KNOLLE, Jochen [DE/US]; 178 Grand
Vien #3, San Francisco, CA 94114 (US). GADEK,
Thomas, R. [US/US]; 2838 Chelsea Drive, Oakland, CA
94611 (US). GOURVEST, Jean-François [FR/FR]; 12,

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: SUBSTITUTED PURINE DERIVATIVES AS INHIBITORS OF CELL ADHESION




(57) Abstract: The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R¹, R² and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of formula (I), their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.



WO 01/02399 A1

Substituted purine derivatives as inhibitors of cell adhesion

5 The present invention relates to compounds of the formula I,



10 in which B, D, E, G, X, Y, Z, R¹, R² and s have the meanings indicated below, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which
15 can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular
20 as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

Human bones are subject to a constant dynamic renovation process comprising bone resorption and bone formation. These processes are controlled by types of cell
25 specialized for these purposes. Bone resorption is based on the destruction of bone matrix by osteoclasts. The majority of bone disorders are based on a disturbed equilibrium between bone formation and bone resorption. Osteoporosis is a disease

characterized by low bone mass and enhanced bone fragility resulting in an increased risk of fractures. It results from a deficit in new bone formation versus bone resorption during the ongoing remodelling process. Conventional osteoporosis treatment includes, for example, the administration of bisphosphonates, estrogens, 5 estrogen/progesterone (hormone replacement therapy or HRT), estrogen agonists/antagonists (selective estrogen receptor modulators or SERMs), calcitonin, vitamin D analogues, parathyroid hormone, growth hormone secretagogues, or sodium fluoride (Jardine et al., Annual Reports in Medicinal Chemistry 31 (1996) 211).

10 Activated osteoclasts are polynuclear cells having a diameter of up to 400 μm , which remove bone matrix. Activated osteoclasts become attached to the surface of the bone matrix and secrete proteolytic enzymes and acids into the so-called "sealing zone", the region between their cell membrane and the bone matrix. The acidic 15 environment and the proteases cause the destruction of the bone. The compounds of the formula I inhibit bone resorption by osteoclasts.

Studies have shown that the attachment of osteoclasts to the bones is controlled by integrin receptors on the cell surface of osteoclasts. Integrins are a superfamily of 20 receptors which include, inter alia, the fibrinogen receptor $\alpha_{\text{IIb}}\beta_3$ on the blood platelets and the vitronectin receptor $\alpha_v\beta_3$. The vitronectin receptor $\alpha_v\beta_3$ is a membrane glycoprotein which is expressed on the cell surface of a number of cells such as endothelial cells, cells of the vascular smooth musculature, osteoclasts and tumor cells. The vitronectin receptor $\alpha_v\beta_3$, which is expressed on the osteoclast membrane, 25 controls the process of attachment to the bones and bone resorption and thus contributes to osteoporosis. $\alpha_v\beta_3$ in this case binds to bone matrix proteins such as osteopontin, bone sialoprotein and thrombospondin which contain the tripeptide motif Arg-Gly-Asp (or RGD).

30 Horton and coworkers describe RGD peptides and an anti-vitronectin receptor antibody (23C6) which inhibit tooth destruction by osteoclasts and the migration of osteoclasts (Horton et al., Exp. Cell. Res. 105 (1991) 268). In: J. Cell Biol. 111 (1992)

1713 Sato et al. describe echistatin, an RGD peptide from snake venom, as a potent inhibitor of bone resorption in a tissue culture and as an inhibitor of osteoclast adhesion to the bones. Fisher et al. (Endocrinology 132 (1993) 1411) and Yamamoto et al. (Endocrinology 139 (1998) 1411) were able to show in the rat that echistatin
5 also inhibits bone resorption in vivo.

It was furthermore shown that the vitronectin $\alpha_v\beta_3$ on human cells of the vascular smooth musculature of the aorta stimulates the migration of these cells into the neointima which finally leads to arteriosclerosis and restenosis after angioplasty
10 (Brown et al., Cardiovascular Res. 28 (1994) 1815). Yue et al. (Pharmacology Reviews and Communications 10 (1998) 9) show the inhibition of neointima formation using an $\alpha_v\beta_3$ antagonist.

Brooks et al. (Cell 79 (1994) 1157) showed that antibodies against $\alpha_v\beta_3$ or $\alpha_v\beta_3$
15 antagonists can cause a shrinkage of tumors by inducing the apoptosis of blood vessel cells during angiogenesis. The vitronectin receptor $\alpha_v\beta_3$ is also involved in the progression of a variety of other types of cancer, and is overexpressed in malignant melanoma cells (Engleman et al., Annual Reports in Medicinal Chemistry 31 (1996) 191). The melanoma invasiveness correlated with this overexpression (Stracke et al.,
20 Encyclopedia of Cancer, volume III, 1855, Academic Press, 1997; Hillis et al., Clinical Science 91 (1996) 639). Carron et al. (Cancer Res. 58 (1998) 1930) describe the inhibition of tumor growth and the inhibition of hypercalcemia of malignancy using an $\alpha_v\beta_3$ antagonist.

25 Friedlander et al. (Science 270 (1995) 1500) describe anti- $\alpha_v\beta_3$ antibodies or $\alpha_v\beta_3$ antagonists which inhibit the bFGF-induced angiogenesis processes in the rat eye, a property which can be used therapeutically in the treatment of retinopathies and in the treatment of psoriasis. Storgard et al. (J. Clin. Invest. 103 (1999) 47) describe the use of $\alpha_v\beta_3$ antagonists in the treatment of arthritic diseases.


30 Influencing of the vitronectin receptor or of the interactions in which it is involved thus offers the possibility of influencing different disease states for whose therapy and

prophylaxis there continues to be a need for suitable pharmaceutical active ingredients.

EP-A-528586 and EP-A-528587 disclose aminoalkyl-substituted or heterocycl-
 5 substituted phenylalanine derivatives, and WO-A-95/32710 discloses aryl derivatives
 as inhibitors of bone resorption by osteoclasts. In WO-A-95/28426 RGD peptides are
 described as inhibitors of bone resorption, angiogenesis and restenosis. International
 Patent Application PCT/EP98/08051 discloses carbamic ester derivatives, and
 International Patent Application PCT/EP99/00242 discloses sulfonamides which are
 10 vitronectin receptor antagonists. Further vitronectin receptor antagonists are
 disclosed in WO-A-98/08840 and WO-A-98/18461. Substituted purine derivatives as
 inhibitors of bone resorption are described in EP-A-853084. Further investigations
 have shown that the compounds of the formula I are particularly strong inhibitors of
 the vitronectin receptor and of bone resorption by osteoclasts.

15

The present invention relates to compounds of the formula I,



20 in which

B is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl,
 (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-,
 fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-,
 25 (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-
 alkylcarbonyl-, (C₅-C₁₄)-arylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-
 (C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-


alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, aminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues B are independent of one another and can be identical or different, or B denotes an

- 5 aromatic or non-aromatic ring system that is fused to the 6-membered ring containing the groups G and Z;


D is -C(O)-N(R⁶)-, -NR⁶-C(O)-, -NR⁶-C(O)-N(R⁶)-, -NR⁶-C(S)-N(R⁶)-, -C(S)-N(R⁶)- or -C(R⁶)=N-N(R⁶)-, where the divalent residues representing D are bonded to the group

- 10 E via the free bond on their right side;

E is a residue from the series consisting of



6



5 $R^6-C(=NR^6)-NR^6$ - and $R^6R^6N-C(=NR^6)-$;

G is N, CH or C((C₁-C₄)-alkyl);

10 X is hydrogen, $-NR^6R^6$, fluorine, chlorine, bromine, $-OR^6$, $-SR^6$, hydroxy-(C₁-C₆)-alkyl-NH-, (hydroxy-(C₁-C₆)-alkyl)₂N-, amino-(C₁-C₆)-alkyl-NH-, (amino-(C₁-C₆)-alkyl)₂N-, hydroxy-(C₁-C₆)-alkyl-O-, hydroxy-(C₁-C₆)-alkyl-S- or $-NH-C(O)-R^6$;

Y has one of the meanings of R⁶ or is fluorine, chlorine, bromine, cyano, $-NR^6R^6$, $-OR^6$, $-SR^6$ or hydroxy-(C₁-C₆)-alkyl-NH-;

15

Z is N or CH;

20 R¹ is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine,

- chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-arylcarbonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;
- 10 R² is -C(O)R⁵, -C(S)R⁵, -S(O)_pR⁵, -P(O)R⁵R^{5'} or a residue of a 4-membered to 8-membered saturated or unsaturated heterocycle which contains 1, 2, 3 or 4 heteroatoms from the series consisting of nitrogen, oxygen and sulfur;
- 15 R³ is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₅-C₁₄)-arylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, aminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues R³ are independent of one another and can be identical or different;
- 25 R⁴ is hydrogen, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-;
- 30 R⁵ and R^{5'} are hydroxy, (C₁-C₈)-alkoxy, (C₅-C₁₄)-aryl-(C₁-C₈)-alkoxy-, (C₁-C₈)-alkylcarbonyloxy-(C₁-C₄)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyloxy-(C₁-C₈)-alkoxy- or -NR⁶R^{6'}, where the residues R⁵ and R^{5'} are independent of one another and can be identical or different;

R^6 and $R^{6'}$ are hydrogen, (C_1-C_{18}) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl-, (C_5-C_{14}) -aryl where in the aryl residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur, or (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl- where in the aryl moiety of the aryl-alkyl- residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur, or R^6 and $R^{6'}$ together with the nitrogen atom to which they are bonded form a 4-membered to 8-membered ring system which in addition to the nitrogen atom to which R^6 and $R^{6'}$ are bonded can contain one, two or three ring heteroatoms from the series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated,

where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

r is zero, one, two, three or four;

s is zero, one, two, three or four;

v is one, two or three;

p is one or two;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

where, instead of the purine structure shown in formula I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present.

All residues and numbers (or indices) which can occur several times in the compounds of the formula I, for example the residues B, R^3 , R^6 , $R^{6'}$ but also all other residues to which this applies, can each independently of one another have the meanings indicated. They can all be identical or different. Likewise, heteroatoms in

heterocyclic rings or substituents in residues which can be present several times can in each case independently of one another have the meanings indicated and can all be identical or different.

- 5 Alkyl residues can be straight-chain or branched and can be saturated or mono-unsaturated or poly-unsaturated. This also applies if they carry substituents or occur as substituents on other residues, for example in alkoxy residues, alkoxycarbonyl residues or arylalkyl residues. Substituted alkyl residues can be substituted in any suitable position. Examples of alkyl residues containing from 1 to 18 carbon atoms
10 are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, hexadecyl and octadecyl, the n-isomers of all these residues, isopropyl, isobutyl, isopentyl, neopentyl, isohexyl, isodecyl, 3-methylpentyl, 2,3,4-trimethylhexyl, sec-butyl, tert-butyl, or tert-pentyl. A preferred group of alkyl residues is formed by the residues methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-
15 butyl and tert-butyl.

Unsaturated alkyl residues can contain one or more, for example one, two or three, double bonds and/or triple bonds. Of course, an unsaturated alkyl residue has to have at least two carbon atoms. Examples of unsaturated alkyl residues are alkenyl
20 residues such as vinyl, 1-propenyl, allyl, butenyl or 3-methyl-2-butenyl, or alkynyl residues such as ethynyl, 1-propynyl or propargyl. Alkyl residues can also be unsaturated when they are substituted. Preferably an unsaturated alkyl residue is mono-unsaturated and contains one double bond or triple bond.

- 25 These statements relating to alkyl residues correspondingly apply to residues which may be regarded as divalent or polyvalent alkyl residues, for example the alkyl moiety in a substituted alkyl residue like hydroxy-alkyl-. The bonds via which the substituents in a substituted alkyl residue are attached to the alkyl moiety and the bond via which the alkyl moiety is attached to its neighbouring group can be located
30 in any desired positions.

Cycloalkyl residues can be monocyclic, bicyclic or tricyclic, i. e., they can be

monocycloalkyl residues, bicycloalkyl residues and tricycloalkyl residues, provided they have a suitable number of carbon atoms and the parent hydrocarbons are stable. A bicyclic or tricyclic cycloalkyl residue has to have at least 4 carbon atoms. Preferably a bicyclic or tricyclic cycloalkyl residue has at least 5 carbon atoms, more preferably at least 6 carbon atoms, and up to the number of carbon atoms specified in the respective definition. Thus, (C₃-C₁₄)-cycloalkyl comprises but is not limited to, for example, (C₃-C₁₄)-monocycloalkyl, (C₆-C₁₄)-bicycloalkyl and (C₆-C₁₄)-tricycloalkyl, and (C₃-C₁₂)-cycloalkyl comprises but is not limited to, for example, (C₃-C₁₂)-monocycloalkyl, (C₆-C₁₂)-bicycloalkyl and (C₆-C₁₂)-tricycloalkyl.

Monocycloalkyl residues are, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl or cyclotetradecyl which can also be substituted by, for example, (C₁-C₄)-alkyl. Examples of substituted cycloalkyl residues which may be mentioned are 4-methylcyclohexyl and 2,3-dimethylcyclopentyl.

Bicycloalkyl residues and tricycloalkyl residues can likewise be unsubstituted or substituted in any desired suitable position, for example by one or more oxo groups and/or one or more identical or different (C₁-C₄)-alkyl groups, for example methyl or isopropyl groups, preferably methyl groups. The bond via which the bicyclic or the tricyclic residue is bonded can be located in any desired position in the molecule; the residue can thus be bonded via a bridgehead atom or an atom in a bridge. The bond via which the residue is bonded can also be located in any desired stereochemical position, for example in an exo-position or an endo-position.

Examples of parent structures of bicyclic ring systems are norbornane (= bicyclo[2.2.1]heptane), bicyclo[2.2.2]octane and bicyclo[3.2.1]octane. An example of a system substituted by an oxo group is camphor (= 1,7,7-trimethyl-2-oxobicyclo[2.2.1]heptane). Examples of parent structures of tricyclic systems are twistane (= tricyclo[4.4.0.0^{3,8}]decane, adamantane (= tricyclo[3.3.1.1^{3,7}]decane), noradamantane (= tricyclo[3.3.1.0^{3,7}]nonane), tricyclo[2.2.1.0^{2,6}]heptane, tricyclo[5.3.2.0^{4,9}]dodecane, tricyclo[5.4.0.0^{2,9}]undecane or

tricyclo[5.5.1.0^{3,11}]tridecane. A residue derived from adamantane can be 1-adamantyl or 2-adamantyl.

(C₅-C₁₄)-Aryl includes heterocyclic (C₅-C₁₄)-aryl residues (= (C₅-C₁₄)-heteroaryl residues) in which one or more of the 5 to 14 ring carbon atoms are replaced by heteroatoms such as nitrogen, oxygen or sulfur, and carbocyclic (C₆-C₁₄)-aryl residues. Examples of carbocyclic (C₆-C₁₄)-aryl residues are phenyl, naphthyl such as 1-naphthyl or 2-naphthyl, biphenyl such as 2-biphenyl, 3-biphenyl or 4-biphenyl, anthryl or fluorenyl, where (C₆-C₁₂)-aryl residues, in particular 1-naphthyl, 2-naphthyl and phenyl, are preferred. If not stated otherwise, aryl residues, in particular phenyl residues, can be unsubstituted or substituted by one or more, preferably one, two or three, identical or different substituents. In particular substituted aryl residues can be substituted by identical or different residues from the series consisting of (C₁-C₈)-alkyl, in particular (C₁-C₄)-alkyl, (C₁-C₈)-alkoxy, in particular (C₁-C₄)-alkoxy, fluorine, chlorine and bromine, nitro, amino, (C₁-C₄)-alkylamino, di-((C₁-C₄)-alkyl)amino, trifluoromethyl, hydroxy, methylenedioxy, cyano, hydroxycarbonyl-, aminocarbonyl-, (C₁-C₄)-alkoxycarbonyl-, phenyl, phenoxy, benzyl, benzyloxy, tetrazolyl, (R⁹O)₂P(O)- and (R⁹O)₂P(O)-O- where R⁹ is hydrogen, (C₁-C₁₀)-alkyl, (C₆-C₁₄)-aryl or (C₆-C₁₄)-aryl-(C₁-C₈)-alkyl. In general, only up to two nitro groups can be present in the compounds of formula I, and similarly all other groups, substituents or heteroatoms mentioned in the definition of the compounds of formula I can only be present in the compounds of formula I in such positions and in such numbers and in such combinations that the resulting molecule is stable and does not exhibit characteristics that are not desired for the intended use.

In monosubstituted phenyl residues the substituent can be located in the 2-position, the 3-position or the 4-position, the 3-position and the 4-position being preferred. If phenyl is disubstituted, the substituents can be in 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. Preferably in disubstituted phenyl residues the two substituents are located in 3,4-position relative to the linkage site. In trisubstituted phenyl residues, the substituents can be in 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-position, 2,4,6-position or 3,4,5-position. Similarly,

naphthyl residues and other aryl residues can be substituted in any desired position, for example a 1-naphthyl residue in the 2-, 3-, 4-, 5-, 6-, 7- and 8-position, a 2-naphthyl residue in the 1-, 3-, 4-, 5-, 6-, 7- and 8-position.

- 5 Beside carbocyclic systems, (C₅-C₁₄)-aryl groups can also be monocyclic or polycyclic, for example monocyclic, bicyclic or tricyclic, aromatic ring systems in which 1, 2, 3, 4 or 5 ring carbon atoms are replaced by heteroatoms, in particular by identical or different heteroatoms from the series consisting of nitrogen, oxygen and sulfur. Examples of heterocyclic (C₅-C₁₄)-aryl groups and (C₅-C₁₄)-heteroaryl groups
- 10 are pyridyl like 2-pyridyl, 3-pyridyl and 4-pyridyl, pyrrolyl like 2-pyrrolyl and 3-pyrrolyl, furyl like 2-furyl and 3-furyl, thienyl like 2-thienyl and 3-thienyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, cinnolinyl, β -carbolinyl, or benzo-fused, cyclopenta-fused,
- 15 cyclohexa-fused or cyclohepta-fused derivatives of these residues. The heterocyclic systems can be substituted in any suitable position by the substituents listed above with respect to carbocyclic aryl systems.

- In the series of these heteroaryl groups, monocyclic or bicyclic aromatic ring systems
- 20 which have 1, 2 or 3 ring heteroatoms, in particular 1 or 2 ring heteroatoms, from the series consisting of nitrogen, oxygen and sulfur and which can be unsubstituted or substituted by 1, 2 or 3 substituents from the series consisting of (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, fluorine, chlorine, nitro, amino, trifluoromethyl, hydroxy, (C₁-C₄)-alkoxycarbonyl-, phenyl, phenoxy, benzyloxy and benzyl, are preferred. Particularly
- 25 preferred here are monocyclic or bicyclic aromatic 5-membered to 10-membered ring systems having 1, 2 or 3 heteroatoms, in particular having 1 or 2 ring heteroatoms, from the series consisting of nitrogen, oxygen and sulfur which can be substituted by 1 to 2 substituents from the series consisting of (C₁-C₄)-alkyl, (C₁-C₄)-alkoxy, phenyl, phenoxy, benzyl and benzyloxy. More particularly preferred are 5-membered or 6-
- 30 membered monocyclic heteroaryl groups and 9-membered or 10-membered bicyclic heteroaryl groups containing 1 or 2, in particular 1, ring heteroatom from the series consisting of nitrogen, oxygen and sulfur which are unsubstituted or substituted as

described before.

The above statements relating to aryl residues also correspondingly apply to the aryl moiety in groups like, for example, aryl-alkyl-. Examples of aryl-alkyl- residues which
5 can also carry in the aryl moiety the substituents listed above, are benzyl, 1-phenylethyl or 2-phenylethyl.

In addition to the above-mentioned heteroaryl groups, as examples of saturated and unsaturated heterocyclic ring systems like 4-membered to 8-membered ring systems
10 from which heterocyclic residues may be derived if they are in line with the definition of the respective group, there may be mentioned azetidine, tetrahydropyran, 1,4-dioxacyclohexane, morpholine, thiomorpholine, piperazine, piperidine, pyrrolidine, dihydroisoxazole, tetrahydroisoxazole, 1,3-dioxolane, 1,2-dithiolane, 2,3-dihydrofuran, 2,5-dihydrofuran, tetrahydrofuran, 2,3-dihydrothiophene, 2,5-
15 dihydrothiophene, tetrahydrothiophene, 2-imidazoline, 3-imidazoline, 4-imidazoline, imidazolidine, 2-oxazoline, 3-oxazoline, 4-oxazoline, oxazolidine, 2-thiazoline, 3-thiazoline, 4-thiazoline, thiazolidine, 2H-thiapyran, 2H-pyran, 4H-pyran.

If in the formulae of an heterocyclic residue representing the group E the bond via
20 which the residue is connected to the group D, and/or the bond via which substituents R^3 are connected to the residue, are not explicitly directed to a specific ring carbon atom but are drawn through a side of the ring this means that the bond via which the residue is connected to the group D and/or the bonds via which the substituents R^3 are connected can be located on any suitable ring carbon atom of the
25 residue. Thus, for example, in the 1-(R^4)-imidazol-2-yl residue and the 1-(R^4)-4,5-dihydroimidazol-2-yl residue representing E the substituents R^3 can be present in the 4-position and/or in the 5-position, in the 1,4,5,6-tetrahydropyrimidin-2-yl residue representing E the substituents R^3 can be present in the 4-position and/or 5-position and/or 6-position, in the indolyl residue the substituents R^3 can be present on any
30 suitable ring carbon atom and the indolyl residue can be bonded via any suitable ring carbon atom, preferably via the 2-position or the 3-position. A 1,3-oxazolyl residue or a 1,3-thiazolyl residue representing E can be 1,3-oxazol-2-yl, 1,3-oxazol-4-yl, 1,3-

oxazol-5-yl, 1,3-thiazol-2-yl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl where the 2-yl residues are preferred, and in all these residues substituents R^3 can be present on any one or on both of the carbon atoms not bonded to the group D.

5 Optically active carbon atoms present in the compounds of the formula I can independently of one another have R configuration or S configuration. The compounds of the formula I can be present in the form of pure enantiomers or pure diastereomers or in the form of mixtures of enantiomers, for example in the form of racemates, or of mixtures of diastereomers. The present invention relates to both
10 pure enantiomers and mixtures of enantiomers as well as to pure diastereomers and mixtures of diastereomers. The invention comprises mixtures of two or of more than two stereoisomers of the formula I, and it comprises all ratios of stereoisomers in the mixtures. Compounds of the formula I containing respective structural units can also be present as E isomers or Z isomers (or trans isomers or cis isomers). The invention
15 relates to both pure E isomers, pure Z isomers, pure cis isomers, pure trans isomers and to E/Z mixtures and cis/trans mixtures in all ratios. The invention also comprises all tautomeric forms of the compounds of the formula I. Diastereomers, including E/Z isomers, can be separated into the individual isomers, for example, by chromatography. Racemates can be separated into the two enantiomers by
20 customary methods, for example, by chromatography on chiral phases or by resolution, for example by crystallization of diastereomeric salts obtained with optically active acids or bases. Stereochemically uniform compounds of the formula I can also be obtained by employing stereochemically uniform starting materials or by using stereoselective reactions.

25 Physiologically tolerable salts of the compounds of formula I are nontoxic salts that are physiologically acceptable, in particular pharmaceutically utilizable salts. Such salts of compounds of the formula I containing acidic groups, for example carboxyl, are, for example, alkali metal salts or alkaline earth metal salts such as, for example,
30 sodium salts, potassium salts, magnesium salts and calcium salts, and also salts with physiologically tolerable quaternary ammonium ions and acid addition salts with ammonia and physiologically tolerable organic amines such as, for example,

triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine. Basic groups in the compounds of the formula I can form acid addition salts, for example with inorganic acids such as hydrochloric acid, sulfuric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as acetic acid, citric acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. Compounds of the formula I which simultaneously contain a basic group and an acidic group, for example a carboxyl group in addition to basic nitrogen atoms, can be present as zwitterions (or betaines or inner salts) which are likewise included by the present invention.


Salts of compounds of the formula I can be obtained by customary methods known to those skilled in the art, for example by combining a compound of the formula I with an inorganic or organic acid or base in a solvent or diluent, or from other salts by cation exchange or anion exchange. A subject of the present invention are also all salts of the compounds of the formula I which, because of low physiologically tolerability, are not directly suitable for use in pharmaceuticals but are suitable, for example, as intermediates for carrying out further chemical modifications of the compounds of the formula I or as starting materials for the preparation of physiologically tolerable salts.

The present invention moreover includes all solvates of compounds of the formula I, for example hydrates or adducts with alcohols, and also derivatives of the compounds of the formula I like esters, prodrugs and other physiologically tolerable derivatives, as well as active metabolites of the compounds of the formula I. The invention relates in particular to prodrugs of the compounds of the formula I which can be converted into compounds of the formula I under physiological conditions. Suitable prodrugs for the compounds of the formula I, i. e. chemically modified derivatives of the compounds of the formula I having properties which are improved in a desired manner, are known to those skilled in the art. More detailed information relating to prodrugs and their preparation is found, for example, in Fleisher et al., Advanced Drug Delivery Reviews 19 (1996) 115; Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; or H. Bundgaard, Drugs of the Future 16 (1991) 443; which are


all incorporated herein by reference. Suitable prodrugs for the compounds of the formula I are especially ester prodrugs and amide prodrugs of carboxylic acid groups, in particular of a COOH group representing R^2 , for example alkyl esters, and also acyl prodrugs and carbamate prodrugs of acylatable nitrogen-containing groups such as amino groups or the tetrahydronaphthyridine group. In the acyl prodrugs or carbamate prodrugs, one or more, for example one or two, hydrogen atoms on nitrogen atoms in such groups are replaced by an acyl group or a carbamate group. Suitable acyl groups and carbamate groups for the acyl prodrugs and carbamate prodrugs are, for example, the groups R^{10} -C(O)- and R^{11} O-C(O)-, in which R^{10} is hydrogen, (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl in which 1 to 5 carbon atoms can be replaced by heteroatoms such as nitrogen, oxygen or sulfur, or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- in which 1 to 5 carbon atoms in the aryl moiety can be replaced by heteroatoms such as nitrogen, oxygen or sulfur, and in which R^{11} has the meanings indicated for R^{10} with the exception of hydrogen.

The present invention is furthermore not restricted to the compounds shown in formula I which contain an actual purine substructure but also includes those analogous compounds which instead of the purine substructure shown in formula I contain a 3-deazapurine substructure, 7-deazapurine substructure or 7-deaza-8-azapurine substructure, i. e. those compounds which instead of the actual purine ring system contain one of the ring systems of formula IIa, formula IIb or formula IIc wherein the 6-membered ring in the compounds of the formula I which contains the groups G and Z and to which the group E-D- is attached is symbolized by the circular arc attached to the group Z and wherein the group R^1 SO₂-NH-CH(R²)-CH₂- is abbreviated as -EAS. All the above and following explanations relating to


17



IIa



IIb



IIc

compounds of the formula I correspondingly apply to these compounds. Unless stated otherwise, if compounds of the formula I are being discussed then the deaza analogs and deaza-aza analogs are also included. Preferably, in the compounds of the invention the actual purine structure shown in formula I is present in which the nitrogen atoms in the 3-position and in the 7-position are actually present and a carbon atom to which the group Y is bonded is actually present in the 8-position.

- 10 The 6-membered ring in the compounds of formula I which can carry substituents B, can be unsubstituted or substituted where in substituted rings the substituents B can be present in any desired position. If the ring is unsubstituted this means that the number s indicating the number of substituents B is zero. In such a case, i. e. if the ring is unsubstituted and the number s is zero, all possible substituent positions on
- 15 that ring which are not occupied by bonds connecting it to the neighbouring groups which are depicted in formula I, carry hydrogen atoms. If the ring is substituted this means that it carries one or more groups or atoms different from hydrogen from those groups and atoms that are listed in the definition of B, and that the number s is different from zero. In such a case, i. e. if the ring is substituted and the number s is
- 20 different from zero, all positions on that ring which are not occupied by substituents B or by bonds connecting it to the adjacent groups depicted in formula I carry hydrogen atoms. The number s preferably is zero, one or two, more preferably zero, i. e. in a more preferred embodiment of the present invention the 6-membered ring containing the groups G and Z does not carry a substituent B.

These statements relating to substituents B correspondingly apply to substituents R^3 which can be present in the residues listed in the definition of the group E. Thus, if a residue listed in the definition of E can carry substituents R^3 it can be unsubstituted or substituted by R^3 where in substituted residues the substituents R^3 can be present in any desired position. If a residue is unsubstituted by R^3 this means that the number r indicating the number of substituents R^3 is zero. In such a case, i. e. if the residue is unsubstituted by R^3 and the number r is zero, all possible substituent positions in that residue which are not occupied by the bond symbolized by a line which connects the residue to its adjacent group D or which are not occupied by groups that are depicted in the formula, carry hydrogen atoms. If the residue is substituted this means that it carries one or more groups or atoms different from hydrogen from those groups and atoms that are listed in the definition of R^3 , and that the number r is different from zero. In such a case, i. e. if the residue is substituted and the number r is different from zero, all positions in that residue which are not occupied by substituents R^3 or by other groups depicted in the formula or by the bond connecting the residue to its neighbouring group D carry hydrogen atoms. Of course, the number r in a specific residue representing E cannot exceed the number of possible substituent positions in that residue. For example, in the imidazol-2-yl residue carrying a group R^4 in position 1 only two substituents R^3 can be present and r can only be 0, 1 or 2. In a 4,5-dihydroimidazol-2-yl residue or a 1,4,5,6-tetrahydropyrimidin-2-yl residue up to four substituents can be present, for example up to four alkyl groups, and r can be 0, 1, 2, 3 or 4. In general the number r preferably is zero, one or two, more preferably zero, i. e. in a more preferred embodiment of the present invention the residues representing E do not carry any substituents R^3 .

25

The number v preferably is 1 or 2, i. e. the group $(<)_v$ in the respective formulae of heterocyclic residues representing E preferably is the group $-\text{CH}_2-$ or $-\text{CH}_2\text{-CH}_2-$.


The groups B preferably are independently of one another hydroxy or $(\text{C}_1\text{-C}_{18})$ -alkyl, more preferably hydroxy or $(\text{C}_1\text{-C}_6)$ -alkyl, particularly preferably hydroxy or $(\text{C}_1\text{-C}_4)$ -alkyl. In case the substituents B denote aromatic or non-aromatic ring systems that are fused (or annelated) to the 6-membered ring containing the groups G and Z such

30


ring systems are preferably fused to the sides of said 6-membered ring which do neither comprise the group G nor the group Z. If aromatic or non-aromatic ring systems are fused to the 6-membered ring containing the groups G and Z preferably one or two, more preferably one, ring systems are fused to said ring. Preferred ring systems that may be fused to the 6-membered ring containing the groups G and Z are the cyclopentane ring, the cyclohexane ring, the benzene ring, the naphthalene ring and the pyridine ring which latter ring may be fused via its carbon atoms 2 and 3 or via its carbon atoms 3 and 4, in particular the benzene ring.

- 10 The group D preferably is $-C(O)-N(R^6)-$, where this divalent residue is bonded to the group E via its nitrogen atom.


The group E preferably is a residue from the series consisting of




and $R^6R^6N-C(=NR^6)-$, more preferably a residue from the series consisting of



and $R^6R^6N-C(=NR^6)-$, particularly preferably a residue from the series consisting of



more particularly preferably the residue



The group G preferably is N or CH, more preferably CH.

5

The group X preferably is hydrogen, $\text{NR}^6\text{R}^{6'}$, hydroxy-($\text{C}_1\text{-C}_6$)-alkyl-NH- or -NH-C(O)- R^6 , more preferably hydrogen, $\text{NR}^6\text{R}^{6'}$ or -NH-C(O)- R^6 , particularly preferably hydrogen or NH_2 , more particularly preferably hydrogen.

10 The group Y preferably is hydrogen.

The group Z preferably is N, i. e. a nitrogen atom.

15 R^1 preferably is ($\text{C}_1\text{-C}_{18}$)-alkyl, ($\text{C}_3\text{-C}_{14}$)-cycloalkyl, ($\text{C}_3\text{-C}_{14}$)-cycloalkyl-($\text{C}_1\text{-C}_4$)-alkyl-, ($\text{C}_5\text{-C}_{14}$)-aryl, ($\text{C}_5\text{-C}_{14}$)-aryl-($\text{C}_1\text{-C}_4$)-alkyl-, ($\text{C}_5\text{-C}_{14}$)-heteroaryl or ($\text{C}_5\text{-C}_{14}$)-heteroaryl-($\text{C}_1\text{-C}_4$)-alkyl-, more preferably ($\text{C}_5\text{-C}_{14}$)-aryl, where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, ($\text{C}_1\text{-C}_6$)-alkyl, ($\text{C}_1\text{-C}_6$)-alkoxy and ($\text{C}_5\text{-C}_{14}$)-aryl.

20

R^2 preferably is -C(O) R^5 . A residue of a heterocycle representing R^2 preferably is one of the residues tetrazolyl, imidazolyl, pyrazolyl, oxazolyl and thiadiazolyl which are bonded via ring carbon atom.

25 The residues R^3 preferably are ($\text{C}_1\text{-C}_6$)-alkyl, ($\text{C}_3\text{-C}_{14}$)-cycloalkyl, ($\text{C}_3\text{-C}_{14}$)-cycloalkyl-($\text{C}_1\text{-C}_8$)-alkyl-, fluorine, chlorine, bromine, cyano, trifluoromethyl, hydroxy or ($\text{C}_1\text{-C}_6$)-alkoxy, more preferably ($\text{C}_1\text{-C}_6$)-alkyl, fluorine, chlorine, bromine, cyano, hydroxy or ($\text{C}_1\text{-C}_6$)-alkoxy, where all residues R^3 are independent of one another and can be identical or different.

R⁴ preferably is hydrogen or (C₁-C₄)-alkyl, more preferably hydrogen.

The residues R⁵ and R^{5'} preferably are independently of one another hydroxy or (C₁-C₈)-alkoxy, more preferably hydroxy or (C₁-C₆)-alkoxy, particularly preferably preferably hydroxy or (C₁-C₆)-alkoxy.

R⁶ and R^{6'} preferably are hydrogen, (C₁-C₆)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl- or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, or R⁶ and R^{6'} together with the nitrogen atom to which they are bonded form a 4-membered to 6-membered ring system which in addition to the nitrogen atom to which R⁶ and R^{6'} are bonded can contain one or two ring heteroatoms from the series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated, where all residues R⁶ and R^{6'} are independent of one another and can be identical or different. More preferably R⁶ and R^{6'} are hydrogen or (C₁-C₄)-alkyl, or R⁶ and R^{6'} together with the nitrogen atom to which they are bonded form a 4-membered to 6-membered ring system which in addition to the nitrogen atom to which R⁶ and R^{6'} are bonded can contain one ring heteroatom from the series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated. Particularly preferably R⁶ and R^{6'} are hydrogen or (C₁-C₄)-alkyl, more particularly preferably R⁶ is hydrogen. The residue of a ring system formed by R⁶ and R^{6'} together with the nitrogen atom to which they are bonded, preferably is derived from a saturated ring system, more preferably it is derived from one of the ring systems pyrrolidine, piperidine, morpholine, thiomorpholine and piperazine. Particularly preferably the residue R⁶R^{6'}N- is one of the residues pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, thiomorpholin-4-yl, piperazin-1-yl and 4-substituted piperazin-1-yl like, for example, 4-(C₁-C₄)-alkyl-piperazin-1-yl.

In the compounds of formula I according to the invention the various groups, residues and numbers can independently of one another have the above preferred definitions or can have one or more of the specific denotations given in their respective definitions or in the general explanations on the respective groups and residues.


Preferred compounds of the present invention are those compounds of the formula I in which one or more of the residues have preferred definitions, or have one or more specific denotations given in their respective definitions or general explanations, all combinations of such preferred definitions and specific denotations being a subject of
5 the present invention.

A group of preferred compounds is formed, for example, by compounds of the formula I in which

B is (C₁-C₁₈)-alkyl or hydroxy, where all residues B are independent of one another
10 and can be identical or different;

D is -C(O)-N(R⁶)-, where this divalent residue is bonded to the group E via its nitrogen atom;

15 E is a residue from the series consisting of



and R⁶R⁶N-C(=NR⁶)-;

20 G is N or CH;

X is hydrogen;

Y is hydrogen;

25

Z is N or CH;

R^1 is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine,
 5 chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-arylcarbonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-
 10 alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

R^2 is -C(O) R^5 ;

15

R^3 is (C₁-C₆)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, cyano, trifluoromethyl, hydroxy or (C₁-C₆)-alkoxy, where all residues R^3 are independent of one another and can be identical or different;

20 R^4 is hydrogen or (C₁-C₆)-alkyl;

R^5 is hydroxy or (C₁-C₈)-alkoxy;

R^6 and $R^{6'}$ are hydrogen, (C₁-C₆)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl where in the aryl residue one, two or three ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur, or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- where in the aryl moiety of the aryl-alkyl- residue one, two or three ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur,

30 or R^6 and $R^{6'}$ together with the nitrogen atom to which they are bonded form a 4-membered to 6-membered ring system which in addition to the nitrogen atom to

which R^6 and $R^{6'}$ are bonded can contain one, two or three ring heteroatoms from the

series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated,

where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

5

r is zero, one, two, three or four;

s is zero, one, two, three or four;

v is one, two or three;

10 in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine

15 structure are not included.


A group of more preferred compounds is formed, for example, by compounds of the formula I in which

B is (C_1-C_6) -alkyl or hydroxy, where all residues B are independent of one another

20 and can be identical or different;

D is $-C(O)-N(R^6)-$, where this divalent residue is bonded to the group E via its nitrogen atom;

25 E is a residue from the series consisting of



and $R^6R^{6'}N-C(-NR^6)-$.

G is N or CH;

X is hydrogen;

5 Y is hydrogen;

Z is N;

R^1 is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-
10 aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-
alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three
times by identical or different substituents from the series consisting of fluorine,
chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-
C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-
15 alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-
arylcarbonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-
arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-
alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-
arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-,
20 (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

R^2 is -C(O) R^5 ;

R^3 is (C₁-C₆)-alkyl, fluorine, chlorine, bromine, cyano, hydroxy or (C₁-C₆)-alkoxy,
25 where all residues R^3 are independent of one another and can be identical or
different;

R^4 is hydrogen or (C₁-C₄)-alkyl;

30 R^5 is hydroxy or (C₁-C₆)-alkoxy;

R^6 and $R^{6'}$ are hydrogen, (C_1-C_6) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl- or (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, or R^6 and $R^{6'}$ together with the nitrogen atom to which they are bonded form a 4-membered to 6-membered ring system which in addition to the nitrogen atom to which R^6 and $R^{6'}$ are bonded can contain one or two
 5 ring heteroatoms from the series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated,
 where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

- 10 r is zero, one, two, three or four;
 s is zero, one or two;


in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

- 15 where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure are not included.

- 20 A group of particularly preferred compounds is formed, for example, by compounds of the formula I in which

D is $-C(O)-N(R^6)-$, where this divalent residue is bonded to the group E via its nitrogen atom;

- 25 E is a residue from the series consisting of



G is CH;

X is hydrogen;

5 Y is hydrogen;

Z is N;

R¹ is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-
10 aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-
alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three
times by identical or different substituents from the series consisting of fluorine,
chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-
C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-
15 alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-
arylcarbonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-
arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-
alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-
arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-,
20 (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

R² is -C(O)R⁵;

R⁴ is hydrogen or (C₁-C₄)-alkyl;

25

R⁵ is hydroxy or (C₁-C₆)-alkoxy;

R⁶ is hydrogen or (C₁-C₄)-alkyl;

30 s is zero;


in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

where in this group of compounds the analogs of the compounds of formula I having
 5 a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure are not included. In this group of compounds the number *r* of substituents in the residue E is zero.

A group of more particularly preferred compounds is formed, for example, by
 10 compounds of the formula I in which

D is -C(O)-NH-, where this divalent residue is bonded to the group E via its nitrogen atom;

15 E is the residue



G is CH;

20

X is hydrogen;

Y is hydrogen;

25 Z is N;

R¹ is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three

chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy and (C₅-C₁₄)-aryl;

R² is -C(O)R⁵;


5

R⁵ is hydroxy or (C₁-C₆)-alkoxy;

s is zero;

10 in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

where in this group of compounds the analogs of the compounds of formula I having a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure are not included. In this group of compounds the number r of substituents in
15 the residue E is zero. This group of compounds can also be represented by the formula Ia




20

wherein R¹ and R⁵ have the before-mentioned meanings.


Further, preferred compounds of the present invention are those compounds in which the asymmetric carbon atom in the formula I to which the groups R² and R¹-SO₂-NH-
25 are bonded, has S configuration, and their physiologically tolerable salts and their prodrugs

- compounds of the formula I are obtainable and which comprise carrying out one or more of the synthesis steps described below. The compounds of the formula I can generally be prepared, for example in the course of a convergent synthesis, by linkage of two or more fragments which can be derived retrosynthetically from the formula I. In the preparation of the compounds of the formula I it can generally be advantageous or necessary in the course of the synthesis to introduce functional groups which could lead to undesired reactions or side reactions in the respective synthesis step, in the form of precursor groups which are later converted into the desired functional groups, or to temporarily block functional groups by a protective group strategy suited to the synthesis problem. Such strategies are well known to those skilled in the art (see, for example, Greene and Wuts, *Protective Groups in Organic Synthesis*, Wiley, 1991). As examples of precursor groups nitro groups and cyano groups may be mentioned which can later be converted by reduction, for example by catalytic hydrogenation, into amino groups and aminomethyl groups, respectively. The protective groups exemplarily mentioned above with respect to functional groups in amino acid residues present in the compounds of formula I correspondingly can be used as protective groups for functional groups during the synthesis of the compounds of formula I.
- For example, for the preparation of a compound of the formula I a building block of the formula III




- in which L^1 is a customary nucleophilically substitutable leaving group, can be used. Suitable groups L^1 are known to those skilled in the art and can be, for example chlorine, bromine, iodine, or a sulfonyloxy group like *p*-toluenesulfonyloxy (-OTos)

methanesulfonyloxy (-OMes) or trifluoromethanesulfonyloxy (-OTf), preferably chlorine or bromine. X and Y in the compounds of formula III are as defined above but functional groups can optionally also be present in the form of precursor groups or can be protected by protective groups. The compound of the formula III is reacted
5 with a building block of the formula IV



wherein R^2 is as defined above but where functional groups in R^2 can optionally also
10 be present in the form of precursor groups or can be protected by protective groups:
In particular, for example, a group R^2 in a compound of the formula I denoting hydroxycarbonyl- (-COOH) is preferably present in a starting compound of the formula IV as an ester like a tert-butyl ester or a methyl ester or an ethyl ester group.
The group L^2 in the compounds of formula IV is hydroxy or a customary
15 nucleophilically substitutable leaving group. Suitable leaving groups L^2 are known to those skilled in the art and can be, for example chlorine, bromine, iodine, -OTos, -OMes or -OTf. The group R^{15} stands for the group R^1-SO_2- wherein R^1 is as defined above, or R^{15} is an amino protecting group. Suitable amino protecting groups are known to those skilled in the art (see, for example, Greene and Wuts, Protective
20 Groups in Organic Synthesis, Wiley, 1991). Examples of amino protecting groups are the benzyloxycarbonyl group, the tert-butoxycarbonyl group or the 9-

- groups can optionally also be present in the form of precursor groups or can be protected by protective groups. The reaction of the compounds of formula III and IV can be carried out according to methods known to those skilled in the art (see, for example, J. March, *Advanced Organic Chemistry*, Fourth Edition, Wiley, 1992, and source literature quoted therein). Preferably, the reaction is carried out in a suitable organic solvent or diluent, for example dichloromethane (DCM), chloroform, tetrahydrofuran (THF), diethyl ether, n-heptane, n-hexane, n-pentane, cyclohexane, diisopropyl ether, methyl tert-butyl ether, acetonitrile, dimethylformamide (DMF), dimethylsulfoxide (DMSO), dioxane, toluene, benzene, ethyl acetate or a mixture of these solvents, if appropriate with addition of a base such as, for example, butyllithium, lithium diisopropylamide (LDA), sodium hydride, sodium amide, potassium tert-butoxide, calcium carbonate, cesium carbonate, triethylamine, N,N-diisopropylethylamine or a complex base (for example sodium amide together with an alcoholate $R^{25}ONa$, where R^{25} is (C_2-C_6) -alkyl or $CH_3CH_2OCH_2CH_2-$). With compounds of the formula IV in which L^2 is hydroxy the reaction is carried out after activation of the hydroxy group, for example by reaction with triphenylphosphine and diethyl azodicarboxylate (DEAD) in THF under the conditions of the well-known Mitsunobu reaction.
- For the preparation of a compound of the formula I in which Z is nitrogen a compound of the formula V is then reacted with a compound of the formula VIa




VIa

- wherein B, D, E, G and s are defined as above but wherein functional groups can optionally also be present in the form of precursor groups or can be protected by protective groups. The reaction of the compounds of the formulae V and VIa can be carried out according to methods well-known to those skilled in the art (see, for

source literature quoted therein). In the reaction of a compound of the formula V with a compound of the formula VIa a nucleophilically substitutable leaving group in one reaction partner is replaced with a nucleophilic nitrogen atom in the other reaction partner as in the case of the reaction of the compounds of formulae III and IV. The above explanations on solvents or bases suitable for the reaction of the compounds of formulae III and IV therefore correspondingly apply to the reaction of the compounds of formulae V and VIa. As a base in the reaction of the compounds of the formulae V and VIa also an excess of the compound of the formula VIa can be used.

- 10 For the preparation of a compound of the formula I in which Z is CH a compound of the formula V is reacted with a compound of the formula VIb




VIb

- 15 wherein B, D, E, G and s are defined as above but wherein functional groups can optionally also be present in the form of precursor groups or can be protected by protective groups. The reaction of the compounds of the formulae V and VIb can be carried out under the conditions of the Stille coupling as described, for example, in Langli et al., Tetrahedron 52 (1996) 5625 or Gundersen, Tetrahedron Lett. 35 (1994)
20 3153, or under the conditions of the Heck coupling as described, for example, in Koyama et al., Nucleic Acids Res., Symp. Ser. 11 (1982) 41 which are all incorporated herein by reference.


The reaction of a compound of the formula V with a compound of the formula VIa or
25 VIb, respectively, leads to a compound of the formula VII,

34



wherein B, D, E, G, X, Y, Z, R^2 , R^{15} and s are defined as above but wherein functional groups can optionally also be present in the form of precursor groups or
 5 can be protected by protective groups. By standard processes precursor groups optionally still present in the compounds of the formula VII are then converted into the desired final groups and/or protective groups optionally still present are then removed. For example, tert-butyl ester groups, especially a tert-butyl ester group which represents the group R^2 in the compound of formula VII and which is a
 10 protected form of hydroxycarbonyl group representing R^2 in the target compound of formula I, can be converted into the carboxylic acid group by treatment with trifluoroacetic acid.

If the group R^{15} in the compound of the formula VII does not stand for a group
 15 R^1-SO_2- that is to be present in the desired target molecule of the formula I but stands for an amino protecting group, a deprotection step is carried out by which the compound of the formula VII is converted into the compound of the formula VIII



20

wherein B, D, E, G, X, Y, Z, R^2 and s are defined as above but wherein functional groups can optionally also be present in the form of precursor groups or can be

protected by protective groups. If, for example, R^{15} is a benzyloxycarbonyl group the conversion of the group $R^{15}NH$ into the group H_2N can be accomplished by catalytic hydrogenation, for example over palladium on charcoal in a solvent like acetic acid or ethanol or methanol, if R^{15} is a 9-fluorenylmethoxycarbonyl group the conversion of
5 the group $R^{15}NH$ into the group H_2N can be accomplished by treatment with piperidine.

For the introduction of the group R^1-SO_2- the compound of the formula VIII is then reacted with a sulfonic acid halide of the formula R^1-SO_2-Hal or a sulfonic acid
10 anhydride of the formula $R^1-SO_2-O-SO_2-R^1$ wherein R^1 is as defined above and Hal denotes fluorine, chlorine or bromine, preferably chlorine. This sulfonylation reaction is preferably carried out in a suitable organic solvent or diluent, for example in dimethylformamide, N-methylpyrrolidone, dichloromethane, chloroform, tetrahydrofuran, dioxane, dimethylsulfoxide, toluene, benzene, ethyl acetate or a
15 mixture of these solvents, optionally with addition of a base such as, for example, triethylamine or N,N-diisopropylethylamine.

In the synthesis of a compound of the formula I it is also possible first to react a compound of the formula III with a compound of the formula VIa or VIb leading to
20 replacement of the group L^1 in the formula III by the 6-membered ring, and subsequently to react the resulting intermediate with a compound of the formula IV.


If desired, with the compounds of the formula VII or with the sulfonylation products of the compounds of the formula VIII further reactions can then be carried out by
25 standard processes, for example acylation reactions or esterification reactions. Further, for example, a substituent X in the 2-position of the purine structure can also be introduced only at the end of the above-described synthesis of the compounds of formula I by methods known per se, for example as described in D. A. Nugiel, J. Org. Chem. 62 (1997) 201 or N. S. Gray, Tetrahedron Lett. 38 (1997) 1161 and the
30 references quoted therein, and a substituent Y in the 8-position can be introduced by methods known per se as described, for example, in E. J. Reist et al., J. Org. Chem. 33 (1968) 1600; J. L. Kelley et al., J. Med. Chem. 33 (1990) 196 or E. Vanotti et al.,

Eur. J. Chem. 29 (1994) 287 which are all incorporated herein by reference. In addition, if desired a compound of the formula VII or a sulfonylation product of a compound of the formula VIII can be converted into a physiologically tolerable salt or a prodrug by standard processes known to those skilled in the art.

5

Compounds of the formula I in which D is $-\text{CO}-\text{NR}^6-$ wherein the nitrogen atom is bonded to the group E, the group G is CH and the group Z is nitrogen can also be prepared via the following route. A compound of the formula V is reacted with an compound of the formula IX to give a compound of the formula X.

10



B, X, Y, R^2 , R^{15} and s in the compounds of formulae IX and X are as defined above but functional groups can optionally also be present in the form of precursor groups or can be protected by protective groups. The group U in the compounds of formula IX is a carboxylic acid group COOH or a suitably protected carboxylic acid group, for example a benzyl ester, tert-butyl ester or silyl ester. If U is a protected carboxylic acid group preferably the protective group is chosen such that it can be deprotected independently from other protected carboxylic acid groups that may be present, for example in R^2 , or from a protecting group R^7 . The reaction of the compounds of the formulae IX and X can be carried out according to methods well known to those skilled in the art (see, for example, J. March, Advanced Organic Chemistry, Fourth Edition, Wiley, 1992, and source literature quoted therein). In the reaction of a compound of the formula IX with a compound of the formula X a nucleophilically substitutable leaving group in one reaction partner is replaced with a nucleophilic nitrogen atom in the other reaction partner as, for example, in the case of the

25

- reaction of the compounds of formulae III and IV. The above explanations on solvents or bases suitable for the reaction of the compounds of formulae III and IV therefore correspondingly apply to the reaction of the compounds of formulae IX and X. As a base in the reaction of the compounds of the formulae IX and X also an
- 5 excess of the compound of the formula IX can be used. If a compound of the formula IX is used in which U is the group COOH the reaction directly leads to a compound of the formula X. Otherwise the compound of the formula X is obtained after removal of the carboxylic acid protecting group present in U according to known methods.
- 10 The carboxylic acid group in the 4-position of the piperidin-1-yl residue in the compounds of the formula I can then be activated, for example by methods used for peptide couplings which are well known to those skilled in the art and which are reviewed, for example, in F. Albericio and L. A. Carpino, *Methods Enzymol.* 289 (1997), 104. Examples of suitable activating agents are O-((cyano-(ethoxycarbonyl)-
- 15 methylen)-amino)-1,1,3,3-tetramethyluronium tetrafluoroborate (TOTU), O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU), or carbodiimides like N,N'-dicyclohexylcarbodiimide or N,N'-diisopropylcarbodiimide. Activation can also favorably be accomplished by converting the carboxylic acid into
- 20 the pentafluorophenyl ester by reaction with N,N'-dicyclohexylcarbodiimide and pentafluorophenol. After activation the compound of the formula X is reacted with a compound of the formula $H-NR^6-E$ in which R^6 and E are as defined above but functional groups can optionally also be present in the form of precursor groups or can be protected by protective groups, to give a compound of the formula VII in
- 25 which D stands for $C(O)-NR^6$ wherein the nitrogen atom is bonded to the group E, the group G stands for CH and the group Z stands for nitrogen. The compound of the formula VII is then converted into the formula I as outlined above.
- 30 The starting compounds of the formulae III, IV, VIa, VIb and IX which are linked to give the compounds of the formula I, are commercially available or can be prepared by or analogously to processes described below or in the literature.

The compounds of the formula I are valuable pharmacologically active compounds which are suitable, for example, for the therapy and prophylaxis of bone disorders, tumor diseases, cardiovascular disorders or inflammatory conditions. The compounds of the formula I and their physiologically tolerable salts and their
5 prodrugs can be administered to animals, preferably to mammals, and in particular to humans as pharmaceuticals for therapy or prophylaxis. They can be administered on their own or in mixtures with one another or in the form of pharmaceutical compositions which permit enteral or parenteral administration and which, as active constituent, contain an efficacious dose of at least one compound of the formula I
10 and/or its physiologically tolerable salts and/or its prodrugs in addition to customary pharmaceutically acceptable carrier substances and/or additives.

The present invention therefore also relates to the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for use as pharmaceuticals,
15 to the use of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for the production of pharmaceuticals for the therapy and prophylaxis of the diseases mentioned above or below, for example for the therapy and prophylaxis of bone disorders, and also to the use of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for the
20 therapy and prophylaxis of these diseases and to methods for such therapy and prophylaxis. The present invention furthermore relates to pharmaceutical compositions (or pharmaceutical preparations) which contain an efficacious dose of at least one compound of the formula I and/or its physiologically tolerable salts and/or its prodrugs and a customary pharmaceutically acceptable carrier.

25

The pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration, however, can also be carried out rectally, for example in the form of suppositories, or
30 parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions emulsions

or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.

The pharmaceutical compositions according to the invention are prepared in a manner known per se and familiar to those skilled in the art, one or more

- 5 compound(s) of the formula I and/or its (their) physiologically tolerable salts and/or its (their) prodrugs being mixed with one or more pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives and, if desired, one or more other pharmaceutically active compounds and being brought into a suitable administration form and dosage form that can be used in human or veterinary
- 10 medicine. For the production of pills, tablets, coated tablets and hard gelatin capsules it is possible to use, for example, lactose, corn starch or derivatives thereof, talc, stearic acid or its salts, etc. Carriers for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carrier substances for the production of solutions, for example injection
- 15 solutions, or of emulsions or syrups are, for example, water, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc. Suitable carriers for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid. The pharmaceutical compositions normally contain about 0.5 to 90 % by weight of the compounds of the formula I and/or their physiologically tolerable salts
- 20 and/or their prodrugs. The amount of the active ingredient of the formula I and/or its physiologically tolerable salts and/or its prodrugs in the pharmaceutical compositions normally is from about 0.2 mg to about 500 mg, preferably from about 1 mg to about 200 mg.
- 25 In addition to the active ingredients of the formula I and/or its physiologically tolerable salts and/or its prodrugs and carriers, the pharmaceutical compositions can contain additives (or auxiliary substances) such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents,
- 30 solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formula I and/or their physiologically tolerable salts and/or their

prodrugs. Furthermore, in addition to at least one compound of the formula I and/or its physiologically tolerable salts and/or its prodrugs, they can also contain one or more other therapeutically or prophylactically active ingredients.

- 5 The compounds of the formula I are antagonists of the vitronectin receptor and inhibitors of cell adhesion. They have, for example, the ability to inhibit the binding of osteoclasts to the bone surface and thereby inhibit bone resorption by osteoclasts. The action of the compounds of the formula I can be demonstrated, for example, in an assay in which the inhibition of the binding of the isolated vitronectin receptor or of
- 10 cells which contain the vitronectin receptor to a ligand of the vitronectin receptor is determined. Details of such an assay are given below. As vitronectin receptor antagonists, the compounds of the formula I and their physiologically tolerable salts and their prodrugs are generally suitable for the therapy and prophylaxis of diseases which are based on the interaction between vitronectin receptors and their ligands in
- 15 cell-cell interaction processes or cell-matrix interaction processes, or which can be influenced by an inhibition of interactions of this type, or for the prevention, alleviation or cure of which an inhibition of interactions of this type is desired. As explained at the beginning, such interactions play a part, for example, in bone resorption, in angiogenesis or in the proliferation of cells of the vascular smooth musculature. The
- 20 compounds of the formula I and their physiologically tolerable salts and their prodrugs are therefore suitable, for example, for the prevention, alleviation or cure of diseases which are caused at least partially by an undesired extent of bone resorption, angiogenesis or proliferation of cells of the vascular smooth musculature.
- 25 Bone diseases for whose treatment and prevention the compounds of the formula I according to the invention can be employed are especially osteoporosis, hypercalcemia, osteopenia, for example caused by metastases, dental disorders, hyperparathyroidism, periarticular erosions in rheumatoid arthritis and Paget's disease. In addition, the compounds of the formula I can be used for the alleviation,
- 30 avoidance or therapy of bone disorders which are caused by a glucocorticoid, steroid or corticosteroid therapy or by a lack of sex hormone(s). All these disorders are

formation and bone destruction and which can be favorably influenced by the inhibition of bone resorption by osteoclasts. The compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs can also favorably be used as inhibitor of bone resorption, for example in the therapy or prophylaxis of

5 osteoporosis, in combination with conventional osteoporosis treatments, for example in combination with agents like bisphosphonates, estrogens, estrogen/progesterone, estrogen agonists/antagonists, calcitonin, vitamin D analogues, parathyroid hormone, growth hormone secretagogues, or sodium fluoride. Administration of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs and

10 of other active ingredients effective in the treatment or prophylaxis of osteoporosis like those listed before can take place simultaneously or sequentially, in any order, and jointly or separately. For use in such a combination treatment or prophylaxis the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs and one or more other active ingredients like those listed before can

15 together be present in a single pharmaceutical composition, for example tablets, capsules or granules, or can be present in two or more separate pharmaceutical compositions which can be contained in a single package or in two or more separate packages. The use of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs in such a combination therapy or prophylaxis and

20 their use in the production of pharmaceuticals for such a combination therapy or prophylaxis are also subjects of the present invention. The invention furthermore relates to pharmaceutical compositions which comprise efficacious amounts of at least one compound of the formula I and/or its physiologically tolerable salts and/or its prodrugs together with at least one other active ingredient effective in the

25 treatment or prophylaxis of osteoporosis or in the inhibition of bone resorption like those listed before, together with a customary pharmaceutically acceptable carrier. The above explanations on pharmaceutical compositions correspondingly apply to such pharmaceutical combination compositions.

30 Apart from use as inhibitors of bone resorption by osteoclasts, the compounds of the formula I and their physiologically tolerable salts and their prodrugs can be used, for example, as inhibitors of tumor growth and tumor metastasis, as antiinflammatories

- for the therapy or prophylaxis of rheumatoid arthritis, for the therapy of psoriasis, for the therapy or prophylaxis of cardiovascular disorders such as arteriosclerosis or restenoses, for the therapy or prophylaxis of nephropathies or retinopathies such as, for example, diabetic retinopathy. As inhibitors of tumor growth or tumor metastasis
- 5 the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs can also favorably be used in combination with conventional cancer therapy. Examples of conventional cancer therapy are given in Bertino (Editor), Encyclopedia of Cancer, Academic Press, 1997 which is incorporated herein by reference. All the above statements relating to the use of the compounds of formula I
- 10 in combination with conventional osteoporosis therapy like, for example, possible modes of administration and pharmaceutical combination compositions, correspondingly apply to the use of the compounds of formula I in combination with conventional cancer therapy.
- 15 When using the compounds of the formula I, the dose can vary within wide limits and, as is customary, is to be suited to the individual conditions in each individual case. It depends, for example, on the compound employed, on the nature and severity of the disease to be treated, or on whether an acute or chronic condition is treated or whether prophylaxis is carried out. In the case of oral administration, the daily dose is
- 20 in general from about 0.01 to about 100 mg/kg, preferably from about 0.1 to about 50 mg/kg, in particular from about 0.1 to about 5 mg/kg, to achieve effective results in an adult weighing about 75 kg (in each case in mg per kg of body weight). Also in the case of intravenous administration the daily dose is in general from about 0.01 to about 100 mg/kg, preferably from about 0.05 to about 10 mg/kg (in each case in mg
- 25 per kg of body weight). The daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behavior it may be necessary to deviate upwards or downwards from the daily dose indicated.
- 30 Apart from use as pharmaceutical active ingredients, the compounds of the formula I can also be used as vehicles or carriers of other active ingredients in order to
- Further information on the function (= drug targeting; see

for example, Targeted Drug Delivery, R. C. Juliano, Handbook of Experimental Pharmacology, Vol. 100, Ed. Born, G. V. R. et al., Springer Verlag which is incorporated herein by reference). The active ingredients to be transported are in particular those which can be used for the treatment of the abovementioned diseases.

The compounds of the formula I and their salts can furthermore be employed for diagnostic purposes, for example in in vitro diagnoses, and as auxiliaries in biochemical investigations in which blocking of the vitronectin receptor or influencing of cell-cell or cell-matrix interactions is desired. They can furthermore be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.


Examples

Abbreviations

| | | |
|----|------|-----------------------|
| 20 | AcOH | acetic acid |
| | DCM | dichloromethane |
| | DMF | N,N-dimethylformamide |
| | EE | ethyl acetate |
| | MeOH | methanol |
| 25 | TFA | trifluoroacetic acid |
| | THF | tetrahydrofuran |

Example 1

30 (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid



a) (2S)-2-Benzyloxycarbonylamino-3-(6-chloro-purin-9-yl)-propionic acid tert-butyl ester

5

To a suspension of 7.73 g (50 mmol) of 6-chloropurine in 350 ml of absolute THF were added 14.43 g (55 mmol) triphenylphosphine at -10 to 0 °C, followed by 9.57 g (55 mmol) of diethyl azodicarboxylate and 14.8 g (50 mmol) of N-benzyloxycarbonyl-L-serine tert-butyl ester in 100 ml of absolute THF, and the mixture was stirred at 0 °C for 48 h. The solvent was evaporated, the residue was dissolved in EE/heptane (2:1), filtered and the solvent was removed in vacuo. The crude product was purified by flash chromatography on silica gel (EE/n-heptane (1:1) and DCM/EE (85:15)). Yield: 6.6 g.

¹H-NMR (200 MHz, D₆-DMSO): δ = 1.30 (s, 9H, C(CH₃)₃); 4.48-4.73 (m, 3H, CH₂-CH-N); 4.98 (s, 2H, CH₂-aryl); 7.19-7.40 (m, 5H, aryl-H); 7.87 (d, 1H, NH); 8.61 + 8.77 (s + s, 2H, C⁶-H + C⁸-H).

MS (FAB): m/e = 432.1 (100 %, (M+H)⁺); 376.0 (60 %).

b) 1-(9-((2S)-2-Benzyloxycarbonylamino-2-tert-butoxycarbonyl-ethyl)-purin-6-yl)-piperidine-4-carboxylic acid

20

To 5.92 g (45.8 mmol) of piperidine-4-carboxylic acid in 200 ml of DMF were added 18.65 g (92 mmol) of N,O-bis-trimethylsilylacetamide. The mixture was brought to room temperature and stirred for 2.5 h. Then 6.6 g (15.3 mmol) of the compound of step a) in 50 ml of DMF were added and the mixture was stirred at room temperature for 18 h. The solvent was removed in vacuo and the residue dissolved in EE and extracted with aqueous KHSO₄/K₂SO₄ solution and saturated brine. The solution was

25

was purified by flash chromatography on silica gel (EE/n-heptane (1:1) and DCM/MeOH/AcOH (100:3:0.5)). Yield: 4.7 g.

MS (ES⁺): m/e = 525.4 (100 %, (M+H)⁺).

- 5 c) (2S)-2-Benzoyloxycarbonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

To 4.65 g (8.87 mmol) of the compound of step b) and 1.45 g (10.65 mmol) of 2-amino-1,4,5,6-tetrahydropyrimidine hydrochloride in 120 ml of absolute DMF were
10 added 3.2 g (9.76 mmol) of O-((cyano-(ethoxycarbonyl)-methylen)-amino)-1,1,3,3-tetramethyluronium-tetrafluoroborate (TOTU) and 4.59 g (6.04 mmol) of N,N-diisopropylethylamine and the mixture was stirred for 5 h at room temperature. 2.66 ml of glacial acetic acid were added and the solvent was removed in vacuo. The residue was dissolved in EE and extracted with aqueous NaHCO₃ solution and brine,
15 the solution was dried over MgSO₄, filtered and the solvent was removed in vacuo. The crude product was purified by flash chromatography on silica gel (DCM/MeOH/AcOH/H₂O (93:7:0.7:0.7)). Yield: 2.4 g.
MS (ES⁺): m/e = 606.5 (100 %, (M+H)⁺); 303.8 (50 %); 275.8 (100 %).

- 20 d) (2S)-2-Amino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

1 g of the compound of step c) was dissolved in 30 ml of glacial acetic acid and hydrogenated over 0.5 g of palladium/charcoal (10 %). The catalyst was filtered off,
25 the solvent was removed in vacuo and the product was purified by flash chromatography on silica gel (DCM/MeOH/AcOH/H₂O (92:8:1.5:1.5)). Yield: 0.76 g.
MS (ES⁺): m/e = 472.3 (10 %, (M+H)⁺); 208.6 (100 %).

- e) (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester
30


To 0.25 g (0.47 mmol) of the compound of step d) in 4 ml of absolute DMF were added at 0 °C 160 mg (0.7 mmol) of naphthalene-1-sulfonyl chloride and 152 mg (1.18 mmol) of N,N-diisopropylethylamine and the mixture was stirred at 0 °C for 3 hours. The solvent was removed in vacuo, the residue was dissolved in EE and the solution was extracted with aqueous NaHCO₃ solution and brine, dried over MgSO₄, filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (DCM/MeOH/AcOH/H₂O (93:7:0.7:0.7)). Yield: 183 mg. MS (ES⁺): m/e = 662.4 (15 %, (M+H)⁺); 331.9 (30 %); 303.8 (100 %).

- 10 f) (2S)-2-(Naphthalene-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid

173 mg of the compound of step e) were dissolved in 40 ml of cooled 95 % TFA and stirred for 30 minutes at 0 °C and then for 40 minutes at room temperature. The TFA was removed in vacuo and the product was three times co-evaporated with toluene and three times with ethanol. Yield: 190 mg (TFA salt). MS (ES⁺): m/e = 606.3 (15 %, (M+H)⁺); 323.3 (20 %); 303.8 (100 %).

Example 2

- 20 (2S)-2-(Naphthalene-2-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid



- 25 a) (2S)-2-(Naphthalene-2-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

The synthesis was carried out analogously to example 1 e) using the compound of example 1, step d) and naphthalene-2-sulfonyl chloride. Yield: 71.3 %.

MS (ES⁺): m/e = 662.4 (50 %, (M+H)⁺); 331.9 (90 %); 303.8 (100 %).

- 5 b) (2S)-2-(Naphthalene-2-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid


The synthesis was carried out analogously to example 1 f) using 80 mg of the compound of step a). Yield: 65.3 mg (TFA salt).

- 10 MS (ES⁺): m/e = 606.3 (10 %, (M+H)⁺); 324.3 (15 %); 303.8 (100 %).

Example 3

(2S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid

15



- a) (2S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

20

The synthesis was carried out analogously to example 1 e) using the compound of example 1, step d) and 4-tert-butyl-benzenesulfonyl chloride. Yield: 62 %.

MS (ES⁺): m/e = 668.5 (30 %, (M+H)⁺); 334.8 (100 %); 306.8 (80 %).


- 25 b) (2S)-2-(4-tert-Butyl-benzenesulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid

The synthesis was carried out analogously to example 1 f) using 62 mg of the compound of step a). Yield: 48 mg (TFA salt).

MS (ES⁺): m/e = 612.4 (15 %, (M+H)⁺); 327.4 (10 %); 306.8 (100 %).

5 Example 4

(2S)-2-(Propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid



10

(2S)-2-(n-Propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

The synthesis was carried out analogously to example 1 e) using the compound of example 1, step d) and propane-1-sulfonyl chloride. Yield: 10 %.

MS (FAB): m/e = 578.4 (100 %, (M+H)⁺); 522.4 (40 %).

b) (2S)-2-(n-Propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid


20

The synthesis was carried out analogously to example 1 f) using 7 mg of the compound of step a). Yield: 6.3 mg (TFA salt).

MS (ES⁺): m/e = 522.4 (15 %, (M+H)⁺); 342.8 (15 %); 261.7 (100 %).

25 Example 5

(2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(4-trifluoromethyl-benzenesulfonylamino)-propionic acid



a) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(4-trifluoromethyl-benzenesulfonylamino)-propionic acid tert-butyl ester

5

The synthesis was carried out analogously to example 1 e) using the compound of example 1, step d) and 4-trifluoromethyl-benzenesulfonyl chloride. Yield: 67 %.

MS (ES⁺): m/e = 680.5 (10 %, (M+H)⁺); 340.9 (100 %).

10 b) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(4-trifluoromethyl-benzenesulfonylamino)-propionic acid


The synthesis was carried out analogously to example 1 f) using 60 mg of the compound of step a). Yield: 53 mg (TFA salt).

15 MS (ES⁺): m/e = 624.4 (10 %, (M+H)⁺); 333.3 (15 %); 312.8 (100 %).

Example 6

(2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(3-trifluoromethyl-benzenesulfonylamino)-propionic acid

20



a) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(3-trifluoromethyl-benzenesulfonylamino)-propionic acid tert-butyl ester

The synthesis was carried out analogously to example 1 e) using the compound of example 1, step d) and 3-trifluoromethyl-benzenesulfonyl chloride. Yield: 61 %.

MS (ES⁺): m/e = 680.5 (10 %, (M+H)⁺); 340.9 (100 %).


b) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(3-trifluoromethyl-benzenesulfonylamino)-propionic acid

The synthesis was carried out analogously to example 1 f) using 55 mg of the compound of step a). Yield: 40 mg (TFA salt).

MS (ES⁺): m/e = 624.4 (10 %, (M+H)⁺); 333.3 (15 %); 312.8 (100 %).

15 Example 7

(2S)-2-Phenylmethanesulfonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid



a) (2S)-2-Phenylmethanesulfonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

The synthesis was carried out analogously to example 1 e) using the compound of example 1, step d) and phenylmethanesulfonyl chloride. Yield: 26 %.

MS (ES⁺): m/e = 626.5 (10 %, (M+H)⁺); 313.9 (45 %); 285.8 (100 %).


b) (2S)-2-Phenylmethanesulfonylamino-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid

The synthesis was carried out analogously to example 1 f) using 55 mg of the compound of step a). Yield: 40 mg (TFA salt).

MS (FAB): $m/e = 570.3$ (100 %, $(M+H)^+$).

Example 8

(2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-trifluoromethanesulfonylamino-propionic acid



a) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-trifluoromethanesulfonylamino-propionic acid tert-butylester

To 53.2 mg (0.1 mmol) of the compound of example 1 d) in 1 ml of absolute DCM were added at $-70\text{ }^{\circ}\text{C}$ 56.5 mg (0.2 mmol) of trifluoromethanesulfonic acid anhydride in 0.5 ml of absolute DCM followed by 38.8 mg (0.3 mmol) of N,N-diisopropylethylamine in 0.5 ml of absolute DCM. The mixture was stirred at $-70\text{ }^{\circ}\text{C}$ for 1 h, then slowly warmed to $0\text{ }^{\circ}\text{C}$ and stirred at $0\text{ }^{\circ}\text{C}$ for 2 h. The solvent was removed in vacuo, the residue was dissolved in EE and the solution was extracted with aqueous NaHCO_3 solution and brine, dried over MgSO_4 , filtered and the solvent was removed in vacuo. The crude product was purified by flash chromatography on silica gel (DCM/MeOH/AcOH/ H_2O (94:6:0.6:0.6)). Yield: 29.2 mg.

MS (ES^+): $m/e = 604.5$ (20 %, $(M+H)^+$); 323.4 (10 %); 302.8 (100 %), 274.8 (45 %).


b) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-trifluoromethanesulfonylamino-propionic acid

The synthesis was carried out analogously to example 1 f) using 29 mg of the compound of step a). Yield: 26 mg (TFA salt).

MS (FAB): $m/e = 548.1$ (100 %, $(M+H)^+$).

Example 9

(2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(2,2,2-trifluoro-ethanesulfonylamino)-propionic acid



a) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(2,2,2-trifluoro-ethanesulfonylamino)-propionic acid tert-butyl ester

The synthesis was carried out analogously to example 1 e) using the compound of example 1, step d) and 2,2,2-trifluoro-ethanesulfonyl chloride. Yield: 75 %.

MS (ES^+): $m/e = 618.2$ (40 %, $(M+H)^+$); 330.2 (15 %); 309.7 (100 %), 281.6 (40 %).


b) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(2,2,2-trifluoro-ethanesulfonylamino)-propionic acid

The synthesis was carried out analogously to example 1 f) using 72 mg of the compound of step a). Yield: 68 mg (TFA salt).

MS (ES^+): $m/e = 562.1$ (8 %, $(M+H)^+$); 302.1 (10 %); 281.6 (100 %).

Example 10

(2S)-2-(2-Methyl-propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid



5

a) 1-(9-((2S)-2-Amino-2-tert-butoxycarbonyl-ethyl)-purin-6-yl)-piperidine-4-carboxylic acid

1.7 g of the compound of example 1 b) in 200 ml of AcOH were hydrogenated over palladium/charcoal (10 %) for 40 min at room temperature. The catalyst was filtered off, the solvent was removed in vacuo and the product was lyophilized. Yield: 1.28 g.

b) 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(2-methyl-propane-1-sulfonylamino)-ethyl)-purin-6-yl)-piperidine-4-carboxylic acid

15

To 160 mg (0.41 mmol) of the compound of step a) in 2 ml of DMF were added 3 equivalents of N,O-bis-trimethylsilylacetamide and the mixture was stirred for 30 minutes at 0 °C and then for 30 minutes at room temperature. 64 mg (0.41 mmol) of 2-methyl-propane-1-sulfonyl chloride were added at 0 °C and the mixture was slowly brought to room temperature and stirred for 2 h. The solvent was removed in vacuo and the crude product was purified by silica gel chromatography (DCM/MeOH/AcOH/H₂O (95:5:0.5:0.5)). Yield: 80 mg (38 %). MS (ES⁺): m/e = 511.3 (100 %, (M+H)⁺); 467.3 (10 %).

c) (2S)-2-(2-Methyl-propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid tert-butyl ester

80 mg (0.157 mmol) of the compound of step b) were dissolved in 2 ml of acetonitrile and treated with 35 mg of N,N'-dicyclohexylcarbodiimide and 29 mg of pentafluorophenol. The mixture was stirred for 30 minutes at room temperature, and the solvent was removed in vacuo. The residue was taken up in 2 ml of DMF and 31 mg 2-amino-1,4,5,6-tetrahydropyrimidine were added. The mixture was stirred for 12 h at room temperature, the solvent was evaporated and the crude product was purified by silica gel chromatography (DCM/MeOH/AcOH/H₂O (95:5:0.5:0.5)). Yield: 45 mg (49 %).

MS (ES⁺): m/e = 592.5 (15 %, (M+H)⁺); 268.8 (100 %).


d) (2S)-2-(2-Methyl-propane-1-sulfonylamino)-3-(6-(4-(1,4,5,6-tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-propionic acid

45 mg (0.076 mmol) of the compound of step c) were dissolved in TFA/H₂O (95:5) and stirred at room temperature for 30 minutes. The solvent was removed in vacuo and the residue was lyophilized. Yield: 100 % (TFA salt).

MS (ES⁺): m/e = 536.3 (15 %, (M+H)⁺); 268.7 (100 %).

Example 11

(2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(toluene-4-sulfonylamino)-propionic acid



a) 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(toluene-4-sulfonylamino)-ethyl)-purin-6-yl)-piperidine-4-carboxylic acid

The synthesis was carried out analogously to example 10 b) using the compound of example 10 a) and toluene-4-sulfonyl chloride. Yield: 37 %.

MS (ES⁺): m/e = 545.2 (100 %, (M+H)⁺); 489.1 (25 %), 443.1 (15 %).

- 5 b) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(toluene-4-sulfonylamino)-propionic acid tert-butyl ester

The synthesis was carried out analogously to example 10 c) using the compound of step a). Yield: 85 %.

- 10 MS (FAB): m/e = 626.3 (100 %, (M+H)⁺); 570.2 (40 %).


- c) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(toluene-4-sulfonylamino)-propionic acid

- 15 The synthesis was carried out analogously to example 10 d) using the compound of step b). Yield: 100 % (TFA salt).

MS (FAB): m/e = 570.3 (20 %, (M+H)⁺); 285.7 (100 %).

Example 12

- 20 (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid



- 25 a) 1-(9-((2S)-2-tert-Butoxycarbonyl-2-(2,4,6-trimethyl-benzenesulfonylamino)-ethyl)-purin-6-yl)-piperidine-4-carboxylic acid

The synthesis was carried out analogously to example 10 b) using the compound of example 10 a) and 2,4,6-trimethyl-benzenesulfonyl chloride. Yield: 60 %.

MS (FAB): $m/e = 573.4$ (100 %, $(M+H)^+$).

- 5 b) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid tert-butyl ester

The synthesis was carried out analogously to example 10 c) using the compound of step a). Yield: 84 %.

- 10 MS (FAB): $m/e = 654.5$ (30 %, $(M+H)^+$); 327.8 (50 %); 299.8 (100 %).

c) (2S)-3-(6-(4-(1,4,5,6-Tetrahydropyrimidin-2-ylcarbamoyl)-piperidin-1-yl)-purin-9-yl)-2-(2,4,6-trimethyl-benzenesulfonylamino)-propionic acid

- 15 The synthesis was carried out analogously to example 10 d) using the compound of step b). Yield: 100 % (TFA salt).

MS (FAB): $m/e = 598.4$ (15 %, $(M+H)^+$); 299.8 (100 %).

20 Pharmacological Testing

1) Kistrin Binding Assay

- 25 The inhibition of the binding of kistrin to human vitronectin receptor (VnR) described below is a test method by which the antagonistic action of the compounds of the invention on the vitronectin receptor $\alpha_v\beta_3$ can be determined ($\alpha_v\beta_3$ ELISA Test; the test method is abbreviated as "K/VnR" in the listing of the test results).

Purification of kistrin

- 30 Kistrin is purified according to the methods of Dennis et al., as described in Proc. Natl. Acad. Sci. USA 87 (1989) 2471 and Proteins: Structure, Function and Genetics 15 (1993) 312.

Purification of human vitronectin receptor ($\alpha_v\beta_3$)

Human vitronectin receptor is obtained from the human placenta according to the method of Pytela et al., *Methods Enzymol.* 144 (1987) 475. Human vitronectin receptor $\alpha_v\beta_3$ can also be obtained from some cell lines (for example from 293 cells, a human embryonic kidney cell line) which are co-transfected with DNA sequences for both subunits α_v and β_3 of the vitronectin receptor. The subunits are extracted with octyl glycoside and then chromatographed through concanavalin A, heparin-Sepharose and S-300.

Monoclonal antibodies

Murine monoclonal antibodies which are specific for the β_3 subunits of the vitronectin receptor, are prepared according to the method of Newman et al., *Blood*, 1985, 227, or by a similar process. The rabbit Fab 2 anti-mouse Fc conjugate to horseradish peroxidase (anti-mouse Fc HRP) was obtained from Pel Freeze (Catalog No. 715 305-1).

ELISA test

The ability of substances to inhibit the binding of kistrin to the vitronectin receptor can be determined using an ELISA test. For this purpose, Nunc 96-well microtiter plates are coated with a solution of kistrin (0.002 mg/ml) according to the method of Dennis et al., as described in *Proteins: Structure, Function and Genetics* 15 (1993) 312. The plates are then washed twice with PBS/0.05 % Tween-20 and blocked by incubating (60 min) with bovine serum albumin (BSA, 0.5 %, RIA grade or better) in buffer solution (Tris-HCl (50 mM), NaCl (100 mM), MgCl₂ (1 mM), CaCl₂ (1 mM), MnCl₂ (1 mM), pH 7). Solutions of known inhibitors and of the test substances are prepared in concentrations from 2×10^{-12} to 2×10^{-6} mol/l in assay buffer (BSA (0.5 %, RIA grade or better); Tris-HCl (50 mM), NaCl (100 mM), MgCl₂ (1 mM), CaCl₂ (1 mM), MnCl₂ (1 mM), pH 7). The blocked plates are emptied, and in each case 0.025 ml of this solution which contains a defined concentration (2×10^{-12} to 2×10^{-6} mol/l) either of a known inhibitor or of a test substance, are added to each well. 0.025 ml of a solution of the vitronectin receptor in assay buffer (0.03 mg/ml) is pipetted into each

well of the plate and the plate is incubated at room temperature for 60-180 min on a shaker. In the meantime, a solution (6 ml/plate) of a murine monoclonal antibody specific for the β_3 subunit of the vitronectin receptor is prepared in assay buffer (0.0015 mg/ml). A second rabbit antibody (0.001 ml of stock solution/6 ml of the murine monoclonal anti- β_3 antibody solution) which is an anti-mouse Fc HRP antibody conjugate is added to this solution, and this mixture of murine anti- β_3 antibody and rabbit anti-mouse Fc HRP antibody conjugate is incubated during the time of the receptor-inhibitor incubation. The test plates are washed four times with PBS solution which contains 0.05 % Tween-20, and in each case 0.05 ml/well of the antibody mixture is pipetted into each well of the plate and incubated for 60-180 min. The plate is washed four times with PBS/0.05 % Tween-20 and then developed with 0.05 ml/well of a PBS solution which contains 0.67 mg/ml of o-phenylenediamine and 0.012 % of H_2O_2 . Alternatively to this, o-phenylenediamine can be employed in a buffer (pH 5) which contains Na_3PO_4 and citric acid. The color development is stopped using 1 N H_2SO_4 (0.05 ml/well). The absorption for each well is measured at 492-405 nm and the data are evaluated by standard methods.

2) Vitronectin/293 Cell Test

In this test the inhibition of binding of 293 cells to human vitronectin (Vn) by the compounds of the invention is determined (the test method is abbreviated as Vn/293 cell test in the listing of the test results).

Purification of human vitronectin

Human vitronectin was isolated from human plasma and purified by affinity chromatography according to the method of Yatohgo et al., Cell Structure and Function 23 (1988) 281.

Cell test

293 cells, a human embryonic kidney cell line, which were cotransfected with DNA sequences for the α_v and β_3 subunits of the vitronectin receptor $\alpha_v\beta_3$, were selected for a high rate of expression ($> 500,000$ $\alpha_v\beta_3$ receptors/cell) according to the FACS

method. The selected cells were cultured and sorted again by means of FACS in order to obtain a stable cell line (15 D) with expression rates $> 1,000,000$ copies of $\alpha_v\beta_3$ per cell.

- 5 A Linbro 96-well tissue culture plate with a flat bottom was coated overnight at 4 °C with human vitronectin (0.01 mg/ml, 0.05 ml/well) in phosphate-buffered saline solution (PBS) and then blocked with 0.5 % strength BSA (bovine serum albumin). Solutions of the test substances from 10^{-10} mol/l to 2×10^{-3} mol/l in glucose-containing DMEM medium were prepared and 0.05 ml/well of the solution were
10 added to the plate in each case. The cells which expressed high levels of $\alpha_v\beta_3$ (for example 15 D) were suspended in glucose-containing DMEM medium and the suspension was adjusted to a content of 25,000 cells/0.05 ml of medium. 0.05 ml of this cell suspension was added to each well and the plate was incubated at 37 °C for 90 min. The plate was washed 3 times with warm PBS in order to remove unbound
15 cells. The bound cells were lysed in citrate buffer (25 mM, pH 5.0) which contained 0.25 % Triton X-100. The hexoseamidase substrate p-nitrophenyl-N-acetyl- β -D-glucosaminide was then added and the plate was incubated at 37 °C for 90 min. The reaction was stopped with a glycine (50 mM)/EDTA (5 mM) buffer (pH 10.4) and the absorption of each well was measured at 405 to 650 nm. The data were analyzed
20 according to standard methods.

3) Pit Assay

- The inhibition of bone resorption by the compounds of the invention can be
25 determined, for example, with the aid of an osteoclast resorption test ("Pit Assay"), for example analogously to WO-A-95/32710 which is incorporated herein by reference.


The following test results (inhibitory concentrations IC_{50}) were obtained.

60

| Compound | K/VnR | Vn/293 cell test | Pit Assay |
|------------|-----------------------|-----------------------|-----------------------|
| | IC ₅₀ (nM) | IC ₅₀ (nM) | IC ₅₀ (nM) |
| Example 1 | 1.9 | 30 | 0.8 |
| Example 2 | 2.5 | 9 | 2.3 |
| Example 3 | 4.5 | 67 | |
| Example 4 | 25 | 1400 | |
| Example 5 | 3.2 | 28 | 15 |
| Example 6 | 3.4 | 42 | |
| Example 7 | 23 | 500 | |
| Example 8 | 85 | | |
| Example 9 | 38 | 2500 | |
| Example 10 | 4.2 | 1120 | |
| Example 11 | 6.5 | 87 | |
| Example 12 | 5 | 38 | 26 |

Patent claims

1. A compound of the formula I




wherein

B is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₅-C₁₄)-arylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, aminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues B are independent of one another and can be identical or different, or B denotes an aromatic or non-aromatic ring system that is fused to the 6-membered ring containing the groups G and Z;

D is -C(O)-N(R⁶)-, -NR⁶-C(O)-, -NR⁶-C(O)-N(R⁶)-, -NR⁶-C(S)-N(R⁶)-, -C(S)-N(R⁶)- or -C(R⁶)=N-N(R⁶)-, where the divalent residues representing D are bonded to the group E via the free bond on their right side;

E is a residue from the series consisting of



$R^6-C(=NR^6)-NR^6$ - and $R^6R^{6'}N-C(=NR^6)-$;

G is N, CH or C((C₁-C₄)-alkyl);

- 5 X is hydrogen, $-NR^6R^{6'}$, fluorine, chlorine, bromine, $-OR^6$, $-SR^6$, hydroxy-(C₁-C₆)-alkyl-NH-, (hydroxy-(C₁-C₆)-alkyl)₂N-, amino-(C₁-C₆)-alkyl-NH-, (amino-(C₁-C₆)-alkyl)₂N-, hydroxy-(C₁-C₆)-alkyl-O-, hydroxy-(C₁-C₆)-alkyl-S- or $-NH-C(O)-R^6$;

- Y has one of the meanings of R^6 or is fluorine, chlorine, bromine, cyano, $-NR^6R^{6'}$,
 10 $-OR^6$, $-SR^6$ or hydroxy-(C₁-C₆)-alkyl-NH-;

Z is N or CH;

- R^1 is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-
 15 aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-
 alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three
 times by identical or different substituents from the series consisting of fluorine,
 chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-
 C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-
 20 alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-
 arylcarbonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-
 arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-
 alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-
 arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-,
 25 (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

R^2 is $-C(O)R^5$, $-C(S)R^5$, $-S(O)_pR^5$, $-P(O)R^5R^{5'}$ or a residue of a 4-membered to 8-
 membered saturated or unsaturated heterocycle which contains 1, 2, 3 or 4
 heteroatoms from the series consisting of nitrogen, oxygen and sulfur;

30

R^3 is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-
 aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl, (C₅-C₁₄)-heteroaryl-(C₁-C₈)-

alkyl-, fluorine, chlorine, bromine, hydroxy, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₅-C₁₄)-arylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, aminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-heteroaryl, where all residues R³ are independent of one another and can be identical or different;

10

R⁴ is hydrogen, (C₁-C₁₀)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-;

R⁵ and R^{5'} are hydroxy, (C₁-C₈)-alkoxy, (C₅-C₁₄)-aryl-(C₁-C₈)-alkoxy-, (C₁-C₈)-alkylcarbonyloxy-(C₁-C₄)-alkoxy-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyloxy-(C₁-C₈)-alkoxy- or -NR⁶R^{6'}, where the residues R⁵ and R^{5'} are independent of one another and can be identical or different;

R⁶ and R^{6'} are hydrogen, (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl where in the aryl residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur, or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- where in the aryl moiety of the aryl-alkyl- residue one, two, three, four or five ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur,

or R⁶ and R^{6'} together with the nitrogen atom to which they are bonded form a 4-membered to 8-membered ring system which in addition to the nitrogen atom to which R⁶ and R^{6'} are bonded can contain one, two or three ring heteroatoms from the series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated,

where all residues R⁶ and R^{6'} are independent of one another and can be identical or different;

r is zero, one, two, three or four;

s is zero, one, two, three or four;

v is one, two or three;

5 p is one or two;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs;

10 where, instead of the purine structure shown in formula I, also a 3-deazapurine structure, a 7-deazapurine structure or a 7-deaza-8-azapurine structure can be present.


2. A compound of the formula I as claimed in claim 1, wherein

15 B is (C₁-C₁₈)-alkyl or hydroxy, where all residues B are independent of one another and can be identical or different;

D is -C(O)-N(R⁶)-, where this divalent residue is bonded to the group E via its nitrogen atom;

20

E is a residue from the series consisting of



and R⁶R^{6'}N-C(=NR⁶)-;

25

G is N or CH;

X is hydrogen;

Y is hydrogen;

Z is N or CH;

5

R^1 is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine,
 10 chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-arylcabonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-
 15 alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

R^2 is -C(O) R^5 ;

20

R^3 is (C₁-C₆)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, fluorine, chlorine, bromine, cyano, trifluoromethyl, hydroxy or (C₁-C₆)-alkoxy, where all residues R^3 are independent of one another and can be identical or different;

25 R^4 is hydrogen or (C₁-C₆)-alkyl;

R^5 is hydroxy or (C₁-C₈)-alkoxy;

R^6 and $R^{6'}$ are hydrogen, (C₁-C₆)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl where in the aryl residue one, two or three ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur or (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl- where in the aryl moiety of the aryl alkyl residue

30

one, two or three ring carbon atoms can be replaced by heteroatoms from the series consisting of nitrogen, oxygen and sulfur,

or R^6 and $R^{6'}$ together with the nitrogen atom to which they are bonded form a 4-membered to 6-membered ring system which in addition to the nitrogen atom to

- 5 which R^6 and $R^{6'}$ are bonded can contain one, two or three ring heteroatoms from the series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated,

where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;

10

r is zero, one, two, three or four;

s is zero, one, two, three or four;

v is one, two or three;

- 15 in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs.


3. A compound of the formula I as claimed in claims 1 and/or 2, wherein

B is (C_1-C_6) -alkyl or hydroxy, where all residues B are independent of one another

- 20 and can be identical or different;

D is $-C(O)-N(R^6)-$, where this divalent residue is bonded to the group E via its nitrogen atom;

- 25 E is a residue from the series consisting of



and $R^6R^{6'}N-C(=NR^6)-$;

G is N or CH;

X is hydrogen;

5 Y is hydrogen;

Z is N;

10 R^1 is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-arylcabonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

R^2 is -C(O) R^5 ;

25 R^3 is (C₁-C₆)-alkyl, fluorine, chlorine, bromine, cyano, hydroxy or (C₁-C₆)-alkoxy, where all residues R^3 are independent of one another and can be identical or different;

R^4 is hydrogen or (C₁-C₄)-alkyl;

30 R^5 is hydroxy or (C₁-C₆)-alkoxy;

R^6 and $R^{6'}$ are hydrogen, (C_1-C_6) -alkyl, (C_3-C_{14}) -cycloalkyl, (C_3-C_{14}) -cycloalkyl- (C_1-C_8) -alkyl- or (C_5-C_{14}) -aryl- (C_1-C_8) -alkyl-, or R^6 and $R^{6'}$ together with the nitrogen atom to which they are bonded form a 4-membered to 6-membered ring system which in addition to the nitrogen atom to which R^6 and $R^{6'}$ are bonded can contain one or two
 5 ring heteroatoms from the series consisting of nitrogen, oxygen and sulfur and which can be unsaturated or saturated,
 where all residues R^6 and $R^{6'}$ are independent of one another and can be identical or different;


- 10 r is zero, one, two, three or four;
 s is zero, one or two;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs.

15

4. A compound of the formula I as claimed in one or more of claims 1 to 3, wherein D is $-C(O)-N(R^6)-$, where this divalent residue is bonded to the group E via its nitrogen atom;

- 20 E is a residue from the series consisting of



G is CH ;

25

X is hydrogen;

Y is hydrogen;

Z is N;

R¹ is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, nitro, hydroxycarbonyl-, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy, (C₁-C₆)-alkoxy-(C₁-C₆)-alkyl-, (C₁-C₆)-alkoxycarbonyl-, (C₁-C₆)-alkylcarbonyl-, (C₁-C₆)-alkylaminocarbonyl-, (C₁-C₆)-alkoxy-(C₁-C₆)-alkoxy-, (C₅-C₁₄)-arylcarbonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylcarbonyl-, (C₁-C₆)-alkanoylamino-, (C₅-C₁₄)-arylsulfonylamino-, (C₁-C₆)-alkylsulfonylamino-, (C₁-C₆)-alkylamino-, di-((C₁-C₆)-alkyl)amino-, (C₁-C₆)-alkylsulfonyl-, (C₁-C₆)-alkylaminosulfonyl-, (C₅-C₁₄)-arylaminosulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylaminosulfonyl-, (C₅-C₁₄)-arylsulfonyl-, (C₅-C₁₄)-aryl-(C₁-C₈)-alkylsulfonyl-, (C₅-C₁₄)-aryl and (C₅-C₁₄)-heteroaryl;

R² is -C(O)R⁵;

R⁴ is hydrogen or (C₁-C₄)-alkyl;

R⁵ is hydroxy or (C₁-C₆)-alkoxy;


R⁶ is hydrogen or (C₁-C₄)-alkyl;

s is zero;

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs.

5. A compound of the formula I as claimed in one or more of claims 1 to 4, wherein D is -C(O)-NH-, where this divalent residue is bonded to the group E via its nitrogen atom;

E is the residue



5 G is CH;

X is hydrogen;

Y is hydrogen;

10

Z is N;

R^1 is (C₁-C₁₈)-alkyl, (C₃-C₁₄)-cycloalkyl, (C₃-C₁₄)-cycloalkyl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-aryl, (C₅-C₁₄)-aryl-(C₁-C₈)-alkyl-, (C₅-C₁₄)-heteroaryl or (C₅-C₁₄)-heteroaryl-(C₁-C₈)-alkyl- where aryl, heteroaryl, cycloalkyl and alkyl can be substituted one, two or three times by identical or different substituents from the series consisting of fluorine, chlorine, bromine, cyano, trifluoromethyl, (C₁-C₆)-alkyl, (C₁-C₆)-alkoxy and (C₅-C₁₄)-aryl;

15 20 R^2 is -C(O) R^5 ;

R^5 is hydroxy or (C₁-C₆)-alkoxy;

s is zero;


25

in all their stereoisomeric forms and mixtures thereof in all ratios, and their physiologically tolerable salts and their prodrugs.

6. A process for the preparation of a compound as claimed in one or more of claims 1

30 to 5, comprising reacting a compound of the formula V with a compound of the

formula VIa or with a compound of the formula VIb



- 5 wherein L^1 is a leaving group, R^{15} is R^1 -SO₂- or an amino protecting group and B, D, E, G, X, R^2 and s are defined as in claims 1 to 5 but where functional groups can also be present in the form of precursor groups or in protected form.
7. A pharmaceutical composition, comprising at least one compound of the formula I
- 10 as claimed in one or more of claims 1 to 5 and/or its physiologically tolerable salts and/or its prodrugs and a pharmaceutically acceptable carrier.
8. A compound of the formula I as claimed in one or more of claims 1 to 5 and/or its physiologically tolerable salts and/or its prodrugs for use as a pharmaceutical.
- 15 9. A compound of the formula I as claimed in one or more of claims 1 to 5 and/or its physiologically tolerable salts and/or its prodrugs for use as a vitronectin receptor antagonist.
- 20 10. A compound of the formula I as claimed in one or more of claims 1 to 5 and/or its physiologically tolerable salts and/or its prodrugs for use as an inhibitor of bone resorption, for the therapy or prophylaxis of osteoporosis, as an inhibitor of tumor growth or tumor metastasis, as an antiinflammatory, or for the therapy or prophylaxis of cardiovascular disorders, restenoses, arteriosclerosis, nephropathies

retinopathies, psoriasis or rheumatoid arthritis.

INTERNATIONAL SEARCH REPORT

Inter 1al Application No
/EP 00/05921

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D473/34 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | EP 0 853 084 A (HOECHST AG ; GENENTECH INC (US)) 15 July 1998 (1998-07-15) cited in the application examples 19,24-26,28,29 --- | 1-10 |
| A | WO 98 31359 A (DUGGAN MARK E ; MERCK & CO INC (US)) 23 July 1998 (1998-07-23) claims 4-13 --- | 1-10 |
| Y | WO 98 18461 A (HOFFMAN WILLIAM F ; DUGGAN MARK E (US); IHLE NATHAN C (US); MERCK &) 7 May 1998 (1998-05-07) cited in the application page 53 --- -/-- | 1-10 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

* & * document member of the same patent family

Date of the actual completion of the international search

11 August 2000

Date of mailing of the international search report

21/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

Inter 1al Application No

T/EP 00/05921

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | WO 95 32710 A (MERCK & CO INC ;HARTMAN GEORGE D (US); DUGGAN MARK E (US); IHLE NA) 7 December 1995 (1995-12-07) cited in the application the whole document | 1-10 |
| A | WO 98 08840 A (HOFFMAN WILLIAM F ;HUTCHINSON JOHN H (US); MEISSNER ROBERT S (US);) 5 March 1998 (1998-03-05) cited in the application the whole document | 1-10 |
| A,P | WO 99 37621 A (CUTHBERTSON ROBERT ANDREW ;SCHEUNEMANN KARLHEINZ (DE); KNOLLE JOCH) 29 July 1999 (1999-07-29) abstract | 1-10 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter: 1st Application No
PCT/EP 00/05921

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|--|--|
| EP 0853084 | A | 15-07-1998 | DE 19653646 A AU 4846697 A BR 9706387 A CA 2225366 A CN 1193623 A CZ 9704114 A HU 9702507 A JP 10182645 A NO 975977 A PL 323969 A | 25-06-1998 25-06-1998 14-03-2000 20-06-1998 23-09-1998 15-07-1998 28-05-1999 07-07-1998 22-06-1998 22-06-1998 |
| WO 9831359 | A | 23-07-1998 | AU 6023198 A EP 1007026 A | 07-08-1998 14-06-2000 |
| WO 9818461 | A | 07-05-1998 | AU 717283 B AU 5088498 A EP 0946164 A US 5919792 A | 23-03-2000 22-05-1998 06-10-1999 06-07-1999 |
| WO 9532710 | A | 07-12-1995 | AU 701776 B AU 2586895 A CA 2190870 A EP 0760658 A JP 10501222 T US 5929120 A US 5741796 A | 04-02-1999 21-12-1995 07-12-1995 12-03-1997 03-02-1998 27-07-1999 21-04-1998 |
| WO 9808840 | A | 05-03-1998 | AU 4086597 A EP 0934305 A US 5981546 A | 19-03-1998 11-08-1999 09-11-1999 |
| WO 9937621 | A | 29-07-1999 | AU 2518199 A | 09-08-1999 |



P.B.5818 - Patentlaan 2
2280 HV Rijswijk (ZH)
☎ (070) 3 40 20 40
TX 31651 epo nl
FAX (070) 3 40 30 16

Europäisches
Patentamt

Zweigstelle
in Den Haag
Recherchen-
abteilung

European
Patent Office

Br.:
The Hague
Search
division

Office européen
des brevets

Département à
La Haye
Division de la
recherche

EK

Kujath, Eckard, Dr.
Aventis Pharma Deutschland GmbH
Patent- und Lizenzabteilung
65926 Frankfurt am Main
ALLEMAGNE

Aventis Pharma
Deutschland GmbH
Patent- und Lizenzabteilung
Gebäude K 801, Frankfurter Main
65926 Frankfurt am Main
Recherchenabteilung K801
Eing. 20. JAN. 2000
☐ W.V.
☐ anlegen
☐ Vert. wie Vorg. / angegeben.

Datum/Date

18.01.00

| | |
|---|--|
| Zeichen/Ref./Réf. 1999/L037 EPA | Anmeldung Nr./Application No./Demande n°/Patent Nr./Patent No./Brevet n° 99112637.6-2117- |
| Anmelder/Applicant/Demandeur/Patentinhaber/Proprietor/Titulaire Hoechst Marion Roussel Deutschland GmbH, et al | |

COMMUNICATION

The European Patent Office herewith transmits as an enclosure the European search report for the above-mentioned European patent application.

If applicable, copies of the documents cited in the European search report are attached.

☒ Additional set(s) of copies of the documents cited in the European search report is (are) enclosed as well.


The following specifications given by the applicant have been approved by the Search Division:

☒ abstract

☒ title

☐ The abstract was modified by the Search Division and the definitive text is attached to this communication.

The following figure will be published together with the abstract: NONE



REFUND OF THE SEARCH FEE

If applicable under Article 10 Rules relating to fees, a separate communication from the Receiving Section on the refund of the search fee will be sent later.





| DOCUMENTS CONSIDERED TO BE RELEVANT | | | |
|---|--|---|--|
| Category | Citation of document with indication, where appropriate, of relevant passages | Relevant to claim | CLASSIFICATION OF THE APPLICATION (Int.Cl.7) |
| Y,D | EP 0 853 084 A (HOECHST AG ; GENENTECH INC (US)) 15 July 1998 (1998-07-15) * examples 19,24-26,28,29 * | 1-10 k | C07D473/34 A61K31/52 |
| A | WO 98 31359 A (DUGGAN MARK E ; MERCK & CO INC (US)) 23 July 1998 (1998-07-23) * claims 4-13 * | 1-10 | |
| Y,D | WO 98 18461 A (HOFFMAN WILLIAM F ; DUGGAN MARK E (US); IHLE NATHAN C (US); MERCK &) 7 May 1998 (1998-05-07) * page 53 * | 1-10 | |
| Y,D | WO 95 32710 A (MERCK & CO INC ; HARTMAN GEORGE D (US); DUGGAN MARK E (US); IHLE NA) 7 December 1995 (1995-12-07) * the whole document * | 1-10 | |
| A,D | WO 98 08840 A (HOFFMAN WILLIAM F ; HUTCHINSON JOHN H (US); MEISSNER ROBERT S (US);) 5 March 1998 (1998-03-05) * the whole document * | 1-10 | TECHNICAL FIELDS SEARCHED (Int.Cl.7) |
| E | WO 99 37621 A (CUTHBERTSON ROBERT ANDREW ; SCHEUNEMANN KARLHEINZ (DE); KNOLLE JOCH) 29 July 1999 (1999-07-29) * abstract * | 1-10 | C07D A61K |
| The present search report has been drawn up for all claims | | | |
| Place of search BERLIN | | Date of completion of the search 11 January 2000 | Examiner Frelon, D |
| CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document | | | |

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 11 2637

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

11-01-2000

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| EP 0853084 | A | 15-07-1998 | DE 19653646 A | 25-06-1998 |
| | | | AU 4846697 A | 25-06-1998 |
| | | | CA 2225366 A | 20-06-1998 |
| | | | CN 1193623 A | 23-09-1998 |
| | | | CZ 9704114 A | 15-07-1998 |
| | | | HU 9702507 A | 28-05-1999 |
| | | | JP 10182645 A | 07-07-1998 |
| | | | NO 975977 A | 22-06-1998 |
| | | | PL 323969 A | 22-06-1998 |
| WO 9831359 | A | 23-07-1998 | AU 6023198 A | 07-08-1998 |
| WO 9818461 | A | 07-05-1998 | AU 5088498 A | 22-05-1998 |
| | | | EP 0946164 A | 06-10-1999 |
| | | | US 5919792 A | 06-07-1999 |
| WO 9532710 | A | 07-12-1995 | AU 701776 B | 04-02-1999 |
| | | | AU 2586895 A | 21-12-1995 |
| | | | CA 2190870 A | 07-12-1995 |
| | | | EP 0760658 A | 12-03-1997 |
| | | | JP 10501222 T | 03-02-1998 |
| | | | US 5929120 A | 27-07-1999 |
| | | | US 5741796 A | 21-04-1998 |
| WO 9808840 | A | 05-03-1998 | AU 4086597 A | 19-03-1998 |
| | | | EP 0934305 A | 11-08-1999 |
| WO 9937621 | A | 29-07-1999 | AU 2518199 A | 09-08-1999 |

26 = 21.10.00

PATENT COOPERATION TREATY

From the INTERNATIONAL SEARCHING AUTHORITY

PCT

NOTIFICATION OF TRANSMITTAL OF
THE INTERNATIONAL SEARCH REPORT
OR THE DECLARATION

(PCT Rule 44.1)

To:

HOECHST MARION ROUSSEL
Attn. VIEILLEFOSSE, Jean C.
102, route de Noisy
F-93235 Romainville Cedex
FRANCE

Date of mailing
(day/month/year)

21/08/2000

Applicant's or agent's file reference

HMR99L037PCT

FOR FURTHER ACTION

See paragraphs 1 and 4 below

International application No.

PCT/EP 00/ 05921

International filing date
(day/month/year)

26/06/2000

Applicant

AVENTIS PHARMA DEUTSCHLAND GMBH et al.

1. ☒ The applicant is hereby notified that the International Search Report has been established and is transmitted herewith.

Filing of amendments and statement under Article 19:

The applicant is entitled, if he so wishes, to amend the claims of the International Application (see Rule 46):

When? The time limit for filing such amendments is normally 2 months from the date of transmittal of the International Search Report; however, for more details, see the notes on the accompanying sheet.

Where? Directly to the International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland
Facsimile No.: (41-22) 740.14.35

For more detailed instructions, see the notes on the accompanying sheet.

2. ☐ The applicant is hereby notified that no International Search Report will be established and that the declaration under Article 17(2)(a) to that effect is transmitted herewith.

3. ☐ With regard to the protest against payment of (an) additional fee(s) under Rule 40.2, the applicant is notified that:

☐ the protest together with the decision thereon has been transmitted to the International Bureau together with the applicant's request to forward the texts of both the protest and the decision thereon to the designated Offices.

☐ no decision has been made yet on the protest; the applicant will be notified as soon as a decision is made.

4. **Further action(s):** The applicant is reminded of the following:

Shortly after 18 months from the priority date, the international application will be published by the International Bureau. If the applicant wishes to avoid or postpone publication, a notice of withdrawal of the international application, or of the priority claim, must reach the International Bureau as provided in Rules 90bis.1 and 90bis.3, respectively, before the completion of the technical preparations for international publication.

Within 19 months from the priority date, a demand for international preliminary examination must be filed if the applicant wishes to postpone the entry into the national phase until 30 months from the priority date (in some Offices even later).

Within 20 months from the priority date, the applicant must perform the prescribed acts for entry into the national phase before all designated Offices which have not been elected in the demand or in a later election within 19 months from the priority date or could not be elected because they are not bound by Chapter II.

Name and mailing address of the International Searching Authority



European Patent Office, P.B. 5818 Patentlaan 2
NL-2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Chantal Meyer

NOTES TO FORM PCT/ISA/220

These Notes are intended to give the basic instructions concerning the filing of amendments under article 19. The Notes are based on the requirements of the Patent Cooperation Treaty, the Regulations and the Administrative Instructions under that Treaty. In case of discrepancy between these Notes and those requirements, the latter are applicable. For more detailed information, see also the PCT Applicant's Guide, a publication of WIPO.

In these Notes, "Article", "Rule", and "Section" refer to the provisions of the PCT, the PCT Regulations and the PCT Administrative Instructions respectively.

INSTRUCTIONS CONCERNING AMENDMENTS UNDER ARTICLE 19

The applicant has, after having received the international search report, one opportunity to amend the claims of the international application. It should however be emphasized that, since all parts of the international application (claims, description and drawings) may be amended during the international preliminary examination procedure, there is usually no need to file amendments of the claims under Article 19 except where, e.g. the applicant wants the latter to be published for the purposes of provisional protection or has another reason for amending the claims before international publication. Furthermore, it should be emphasized that provisional protection is available in some States only.

What parts of the international application may be amended?

Under Article 19, only the claims may be amended.

During the international phase, the claims may also be amended (or further amended) under Article 34 before the International Preliminary Examining Authority. The description and drawings may only be amended under Article 34 before the International Examining Authority.

Upon entry into the national phase, all parts of the international application may be amended under Article 28 or, where applicable, Article 41.

When?

Within 2 months from the date of transmittal of the international search report or 16 months from the priority date, whichever time limit expires later. It should be noted, however, that the amendments will be considered as having been received on time if they are received by the International Bureau after the expiration of the applicable time limit but before the completion of the technical preparations for international publication (Rule 46.1).

Where not to file the amendments?

The amendments may only be filed with the International Bureau and not with the receiving Office or the International Searching Authority (Rule 46.2).

Where a demand for international preliminary examination has been/is filed, see below.

How?

Either by cancelling one or more entire claims, by adding one or more new claims or by amending the text of one or more of the claims as filed.

A replacement sheet must be submitted for each sheet of the claims which, on account of an amendment or amendments, differs from the sheet originally filed.

All the claims appearing on a replacement sheet must be numbered in Arabic numerals. Where a claim is cancelled, no renumbering of the other claims is required. In all cases where claims are renumbered, they must be renumbered consecutively (Administrative Instructions, Section 205(b)).

The amendments must be made in the language in which the international application is to be published.

What documents must/may accompany the amendments?

Letter (Section 205(b)):

The amendments must be submitted with a letter.

The letter will not be published with the international application and the amended claims. It should not be confused with the "Statement under Article 19(1)" (see below, under "Statement under Article 19(1)").

The letter must be in English or French, at the choice of the applicant. However, if the language of the international application is English, the letter must be in English; if the language of the international application is French, the letter must be in French.

The letter must indicate the differences between the claims as filed and the claims as amended. It must, in particular, indicate, in connection with each claim appearing in the international application (it being understood that identical indications concerning several claims may be grouped), whether

- (i) the claim is unchanged;
- (ii) the claim is cancelled;
- (iii) the claim is new;
- (iv) the claim replaces one or more claims as filed;
- (v) the claim is the result of the division of a claim as filed.

The following examples illustrate the manner in which amendments must be explained in the accompanying letter:

1. [Where originally there were 48 claims and after amendment of some claims there are 51]:
"Claims 1 to 29, 31, 32, 34, 35, 37 to 48 replaced by amended claims bearing the same numbers; claims 30, 33 and 36 unchanged; new claims 49 to 51 added."
2. [Where originally there were 15 claims and after amendment of all claims there are 11]:
"Claims 1 to 15 replaced by amended claims 1 to 11."
3. [Where originally there were 14 claims and the amendments consist in cancelling some claims and in adding new claims]:
"Claims 1 to 6 and 14 unchanged; claims 7 to 13 cancelled; new claims 15, 16 and 17 added." or
"Claims 7 to 13 cancelled; new claims 15, 16 and 17 added; all other claims unchanged."
4. [Where various kinds of amendments are made]:
"Claims 1-10 unchanged; claims 11 to 13, 18 and 19 cancelled; claims 14, 15 and 16 replaced by amended claim 14; claim 17 subdivided into amended claims 15, 16 and 17; new claims 20 and 21 added."

"Statement under article 19(1)" (Rule 46.4)

The amendments may be accompanied by a statement explaining the amendments and indicating any impact that such amendments might have on the description and the drawings (which cannot be amended under Article 19(1)).

The statement will be published with the international application and the amended claims.

It must be in the language in which the international application is to be published.

It must be brief, not exceeding 500 words if in English or if translated into English.

It should not be confused with and does not replace the letter indicating the differences between the claims as filed and as amended. It must be filed on a separate sheet and must be identified as such by a heading, preferably by using the words "Statement under Article 19(1)."

It may not contain any disparaging comments on the international search report or the relevance of citations contained in that report. Reference to citations, relevant to a given claim, contained in the international search report may be made only in connection with an amendment of that claim.

Consequence if a demand for international preliminary examination has already been filed

If, at the time of filing any amendments under Article 19, a demand for international preliminary examination has already been submitted, the applicant must preferably, at the same time of filing the amendments with the International Bureau, also file a copy of such amendments with the International Preliminary Examining Authority (see Rule 62.2(a), first sentence).

Consequence with regard to translation of the international application for entry into the national phase

The applicant's attention is drawn to the fact that, where upon entry into the national phase, a translation of the claims as amended under Article 19 may have to be furnished to the designated/elected Offices, instead of, or in addition to, the translation of the claims as filed.

For further details on the requirements of each designated/elected Office, see Volume II of the PCT Applicant's Guide.

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

| | | |
|--|--|--|
| Applicant's or agent's file reference HMR99L037PCT | FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below. | |
| International application No. PCT/EP 00/ 05921 | International filing date (day/month/year) 26/06/2000 | (Earliest) Priority Date (day/month/year) 02/07/1999 |
| Applicant AVENTIS PHARMA DEUTSCHLAND GMBH et al. | | |

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International Application No

/EP 00/05921

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D473/34 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | EP 0 853 084 A (HOECHST AG ; GENENTECH INC (US)) 15 July 1998 (1998-07-15) cited in the application examples 19,24-26,28,29 --- | 1-10 |
| A | WO 98 31359 A (DUGGAN MARK E ; MERCK & CO INC (US)) 23 July 1998 (1998-07-23) claims 4-13 --- | 1-10 |
| Y | WO 98 18461 A (HOFFMAN WILLIAM F ; DUGGAN MARK E (US); IHLE NATHAN C (US); MERCK &) 7 May 1998 (1998-05-07) cited in the application page 53 --- -/- | 1-10 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 August 2000

Date of mailing of the international search report

21/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

T/EP 00/05921

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category ° | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | WO 95 32710 A (MERCK & CO INC ;HARTMAN GEORGE D (US); DUGGAN MARK E (US); IHLE NA) 7 December 1995 (1995-12-07) cited in the application the whole document ---- | 1-10 |
| A | WO 98 08840 A (HOFFMAN WILLIAM F ;HUTCHINSON JOHN H (US); MEISSNER ROBERT S (US);) 5 March 1998 (1998-03-05) cited in the application the whole document ---- | 1-10 |
| A,P | WO 99 37621 A (CUTHBERTSON ROBERT ANDREW ;SCHEUNEMANN KARLHEINZ (DE); KNOLLE JOCH) 29 July 1999 (1999-07-29) abstract ----- | 1-10 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

T/EP 00/05921

| Patent document cited in search report | | Publication date | Patent family m mber(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| EP 0853084 | A | 15-07-1998 | DE 19653646 A | 25-06-1998 |
| | | | AU 4846697 A | 25-06-1998 |
| | | | BR 9706387 A | 14-03-2000 |
| | | | CA 2225366 A | 20-06-1998 |
| | | | CN 1193623 A | 23-09-1998 |
| | | | CZ 9704114 A | 15-07-1998 |
| | | | HU 9702507 A | 28-05-1999 |
| | | | JP 10182645 A | 07-07-1998 |
| | | | NO 975977 A | 22-06-1998 |
| | | | PL 323969 A | 22-06-1998 |
| WO 9831359 | A | 23-07-1998 | AU 6023198 A | 07-08-1998 |
| | | | EP 1007026 A | 14-06-2000 |
| WO 9818461 | A | 07-05-1998 | AU 717283 B | 23-03-2000 |
| | | | AU 5088498 A | 22-05-1998 |
| | | | EP 0946164 A | 06-10-1999 |
| | | | US 5919792 A | 06-07-1999 |
| WO 9532710 | A | 07-12-1995 | AU 701776 B | 04-02-1999 |
| | | | AU 2586895 A | 21-12-1995 |
| | | | CA 2190870 A | 07-12-1995 |
| | | | EP 0760658 A | 12-03-1997 |
| | | | JP 10501222 T | 03-02-1998 |
| | | | US 5929120 A | 27-07-1999 |
| | | | US 5741796 A | 21-04-1998 |
| WO 9808840 | A | 05-03-1998 | AU 4086597 A | 19-03-1998 |
| | | | EP 0934305 A | 11-08-1999 |
| | | | US 5981546 A | 09-11-1999 |
| WO 9937621 | A | 29-07-1999 | AU 2518199 A | 09-08-1999 |

INTERNATIONAL SEARCH REPORT

International Application No

T/EP 00/05921

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D473/34 A61K31/52

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | EP 0 853 084 A (HOECHST AG ; GENENTECH INC (US)) 15 July 1998 (1998-07-15) cited in the application examples 19,24-26,28,29 ---- | 1-10 |
| A | WO 98 31359 A (DUGGAN MARK E ; MERCK & CO INC (US)) 23 July 1998 (1998-07-23) claims 4-13 ---- | 1-10 |
| Y | WO 98 18461 A (HOFFMAN WILLIAM F ; DUGGAN MARK E (US); IHLE NATHAN C (US); MERCK &) 7 May 1998 (1998-05-07) cited in the application page 53 ----- -/-- | 1-10 |



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 August 2000

Date of mailing of the international search report

21/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

T/EP 00/05921

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | WO 95 32710 A (MERCK & CO INC ;HARTMAN GEORGE D (US); DUGGAN MARK E (US); IHLE NA) 7 December 1995 (1995-12-07) cited in the application the whole document ---- | 1-10 |
| A | WO 98 08840 A (HOFFMAN WILLIAM F ;HUTCHINSON JOHN H (US); MEISSNER ROBERT S (US);) 5 March 1998 (1998-03-05) cited in the application the whole document ---- | 1-10 |
| A,P | WO 99 37621 A (CUTHBERTSON ROBERT ANDREW ;SCHEUNEMANN KARLHEINZ (DE); KNOLLE JOCH) 29 July 1999 (1999-07-29) abstract ----- | 1-10 |

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 00/05921

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|----------------------------|---------------------|
| EP 0853084 | A | 15-07-1998 | DE 19653646 A | 25-06-1998 |
| | | | AU 4846697 A | 25-06-1998 |
| | | | BR 9706387 A | 14-03-2000 |
| | | | CA 2225366 A | 20-06-1998 |
| | | | CN 1193623 A | 23-09-1998 |
| | | | CZ 9704114 A | 15-07-1998 |
| | | | HU 9702507 A | 28-05-1999 |
| | | | JP 10182645 A | 07-07-1998 |
| | | | NO 975977 A | 22-06-1998 |
| | | | PL 323969 A | 22-06-1998 |
| WO 9831359 | A | 23-07-1998 | AU 6023198 A | 07-08-1998 |
| | | | EP 1007026 A | 14-06-2000 |
| WO 9818461 | A | 07-05-1998 | AU 717283 B | 23-03-2000 |
| | | | AU 5088498 A | 22-05-1998 |
| | | | EP 0946164 A | 06-10-1999 |
| | | | US 5919792 A | 06-07-1999 |
| WO 9532710 | A | 07-12-1995 | AU 701776 B | 04-02-1999 |
| | | | AU 2586895 A | 21-12-1995 |
| | | | CA 2190870 A | 07-12-1995 |
| | | | EP 0760658 A | 12-03-1997 |
| | | | JP 10501222 T | 03-02-1998 |
| | | | US 5929120 A | 27-07-1999 |
| | | | US 5741796 A | 21-04-1998 |
| WO 9808840 | A | 05-03-1998 | AU 4086597 A | 19-03-1998 |
| | | | EP 0934305 A | 11-08-1999 |
| | | | US 5981546 A | 09-11-1999 |
| WO 9937621 | A | 29-07-1999 | AU 2518199 A | 09-08-1999 |